uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q17.359 | Q17 | What gene does the drug Pipecuronium target? | The drug Pipecuronium targets 5 genes: CHRNB1, CHRNA1, CHRND, CHRNE and CHRNG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pipecuronium%" OR LOWER(tradeNames_string) LIKE "%pipecuronium%" OR LOWER(drugSynonyms_string) LIKE "%pipecuronium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_544', 'drugName': 'Pipecuronium', 'tradeNames_string': '', 'drugSynonyms_string': 'Pipecuronium', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_5171', 'drugName': 'Pipecuronium Bromide', 'tradeNames_string': 'Arduan', 'drugSynonyms_string': 'Pipecurium bromide, Pipecuronium bromide, Pipecuronium bromide anhydrous, Pipecuronium bromide dihydrate, Pipecuronium bromide hydrate, RGH 1106, RGH-1106', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.114 | Q17 | What gene does the drug Imgn-388 target? | The drug Imgn-388 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ITGAV. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%imgn-388%" OR LOWER(tradeNames_string) LIKE "%imgn-388%" OR LOWER(drugSynonyms_string) LIKE "%imgn-388%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4521', 'drugName': 'Imgn-388', 'tradeNames_string': '', 'drugSynonyms_string': 'IMGN-388, Imgn-388', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'ITGAV (ENSG00000138448)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1440 | Q17 | What gene does the drug Metoprolol Succinate target? | The drug Metoprolol Succinate targets the gene ADRB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%metoprolol succinate%" OR LOWER(tradeNames_string) LIKE "%metoprolol succinate%" OR LOWER(drugSynonyms_string) LIKE "%metoprolol succinate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2286', 'drugName': 'Metoprolol Succinate', 'tradeNames_string': 'Kapspargo sprinkle, Metoprolol succinate, Toprol, Toprol Xl, Toprol-xl', 'drugSynonyms_string': 'H 93/26 SUCCINATE, Metoprolol hemisuccinate, Metoprolol succinate, Seloken-zok, Selozok', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Angina Pectoris (EFO_0003913), Aortic Stenosis (EFO_0000266), Heart Failure (EFO_0003144), Duchenne Muscular Dystrophy (MONDO_0010679), Hypertension (EFO_0000537), Chronic Obstructive Pulmonary Disease (EFO_0000341), Fish-Eye Disease (Orphanet_79292), Hypertrophic Cardiomyopathy (EFO_0000538), Mitral Regurgitation (HP_0001653), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1840 | Q17 | What gene does the drug Paclitaxel Poliglumex target? | The drug Paclitaxel Poliglumex is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 15 genes: TUBB, TUBA4A, TUBA3E, TUBB3, TUBB4B, TUBB2A, TUBA1A, TUBA1C, TUBB1, TUBB2B, TUBB8, TUBB6, TUBB4A, TUBA3C and TUBA1B | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%paclitaxel poliglumex%" OR LOWER(tradeNames_string) LIKE "%paclitaxel poliglumex%" OR LOWER(drugSynonyms_string) LIKE "%paclitaxel poliglumex%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2595', 'drugName': 'Paclitaxel Poliglumex', 'tradeNames_string': 'Xyotax', 'drugSynonyms_string': 'CT-2103, L-polyglutamic paclitaxel, Opaxio, PG-TXL, Paclitaxel conjugate with poly-l-glutamic acid, Paclitaxel poliglumex', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Fallopian Tube Cancer (MONDO_0002158), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Undifferentiated Carcinoma (EFO_0006772), Colorectal Cancer (MONDO_0005575), Lung Cancer (MONDO_0008903), Non-Small Cell Lung Carcinoma (EFO_0003060), Squamous Cell Carcinoma (EFO_0000707), Peritoneum Cancer (MONDO_0002087), Brain Neoplasm (EFO_0003833), Endometrioid Carcinoma (EFO_0000466), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 15}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.952 | Q17 | What gene does the drug Glycopyrrolate target? | The drug Glycopyrrolate targets 2 genes: CHRM1 and CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%glycopyrrolate%" OR LOWER(tradeNames_string) LIKE "%glycopyrrolate%" OR LOWER(drugSynonyms_string) LIKE "%glycopyrrolate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2996', 'drugName': 'Glycopyrronium', 'tradeNames_string': '', 'drugSynonyms_string': 'Glycopyrrolate cation, Glycopyrrolate ion, Glycopyrronium, Glycopyrronium cation, Glycopyrronium ion, Glycopyrronium, erythro-', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Chronic Bronchitis (EFO_0006505), Cerebral Palsy (EFO_1000632), Burn (EFO_0009516), Drooling (HP_0002307), Chronic Obstructive Pulmonary Disease (EFO_0000341), Covid-19 (MONDO_0100096), Airway Obstruction (HP_0006536), Kidney Disease (EFO_0003086), Cardiac Arrhythmia (EFO_0004269), Hyperhidrosis (HP_0000975), Depressive Disorder (MONDO_0002050), Peptic Ulcer Disease (MONDO_0004247), Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2995', 'drugName': 'Glycopyrronium', 'tradeNames_string': '', 'drugSynonyms_string': 'Glycopyrrolate cation, Glycopyrrolate ion, Glycopyrronium, Glycopyrronium cation, Glycopyrronium ion, Glycopyrronium, erythro-', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Chronic Bronchitis (EFO_0006505), Cerebral Palsy (EFO_1000632), Burn (EFO_0009516), Drooling (HP_0002307), Chronic Obstructive Pulmonary Disease (EFO_0000341), Covid-19 (MONDO_0100096), Airway Obstruction (HP_0006536), Kidney Disease (EFO_0003086), Cardiac Arrhythmia (EFO_0004269), Hyperhidrosis (HP_0000975), Depressive Disorder (MONDO_0002050), Peptic Ulcer Disease (MONDO_0004247), Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1139', 'drugName': 'Glycopyrrolate', 'tradeNames_string': 'Cuvposa, Dartisla odt, Glycopyrrolate, Glyrx-pf, Lonhala magnair kit, Robinul, Robinul forte, Robinul fte, Seebri, Sialanar', 'drugSynonyms_string': 'AD-237, AHR-504, CHF-5259, CHF5259, Glycopyrrolate, Glycopyrrolate, erythro-, Glycopyrrone bromide, Glycopyrronium (as bromide), Glycopyrronium bromide, NSC-250836, NSC-251251, NSC-251252, NVA-237, NVA237, Nodapton, ORG-NC-45, PT-001, PT001, Robanul, Tarodyl, Tarodyn', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Burn (EFO_0009516), Drooling (HP_0002307), Chronic Obstructive Pulmonary Disease (EFO_0000341), Kidney Disease (EFO_0003086), Airway Obstruction (HP_0006536), Depressive Disorder (MONDO_0002050), Hyperhidrosis (HP_0000975), Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1138', 'drugName': 'Glycopyrrolate', 'tradeNames_string': 'Cuvposa, Dartisla odt, Glycopyrrolate, Glyrx-pf, Lonhala magnair kit, Robinul, Robinul forte, Robinul fte, Seebri, Sialanar', 'drugSynonyms_string': 'AD-237, AHR-504, CHF-5259, CHF5259, Glycopyrrolate, Glycopyrrolate, erythro-, Glycopyrrone bromide, Glycopyrronium (as bromide), Glycopyrronium bromide, NSC-250836, NSC-251251, NSC-251252, NVA-237, NVA237, Nodapton, ORG-NC-45, PT-001, PT001, Robanul, Tarodyl, Tarodyn', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Burn (EFO_0009516), Drooling (HP_0002307), Chronic Obstructive Pulmonary Disease (EFO_0000341), Kidney Disease (EFO_0003086), Airway Obstruction (HP_0006536), Depressive Disorder (MONDO_0002050), Hyperhidrosis (HP_0000975), Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1186 | Q17 | What gene does the drug Tavapadon target? | The drug Tavapadon is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: DRD5 and DRD1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tavapadon%" OR LOWER(tradeNames_string) LIKE "%tavapadon%" OR LOWER(drugSynonyms_string) LIKE "%tavapadon%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2056', 'drugName': 'Tavapadon', 'tradeNames_string': '', 'drugSynonyms_string': 'CVL-751, Cvl-751, PF-06649751, Pf-06649751, Tavapadon', 'linkedDiseasesDrug_string': 'Kidney Disease (EFO_0003086), Liver Disease (EFO_0001421), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'DRD1 (ENSG00000184845), DRD5 (ENSG00000169676)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2057', 'drugName': 'Tavapadon', 'tradeNames_string': '', 'drugSynonyms_string': 'CVL-751, Cvl-751, PF-06649751, Pf-06649751, Tavapadon', 'linkedDiseasesDrug_string': 'Kidney Disease (EFO_0003086), Liver Disease (EFO_0001421), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'DRD1 (ENSG00000184845), DRD5 (ENSG00000169676)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.456 | Q17 | What gene does the drug Vb-201 target? | The drug Vb-201 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: CD14 and TLR2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vb-201%" OR LOWER(tradeNames_string) LIKE "%vb-201%" OR LOWER(drugSynonyms_string) LIKE "%vb-201%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5798', 'drugName': 'Vb-201', 'tradeNames_string': '', 'drugSynonyms_string': 'Vb 201, Vb-201', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Ulcerative Colitis (EFO_0000729), Covid-19 (MONDO_0100096)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'TLR2 (ENSG00000137462), CD14 (ENSG00000170458)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5799', 'drugName': 'Vb-201', 'tradeNames_string': '', 'drugSynonyms_string': 'Vb 201, Vb-201', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Ulcerative Colitis (EFO_0000729), Covid-19 (MONDO_0100096)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'TLR2 (ENSG00000137462), CD14 (ENSG00000170458)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.876 | Q17 | What gene does the drug Demecarium Bromide target? | The drug Demecarium Bromide targets the gene ACHE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%demecarium bromide%" OR LOWER(tradeNames_string) LIKE "%demecarium bromide%" OR LOWER(drugSynonyms_string) LIKE "%demecarium bromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4088', 'drugName': 'Demecarium Bromide', 'tradeNames_string': 'Humorsol, Tosmilen', 'drugSynonyms_string': 'BC-48, Demecarium bromide, Demekastigmine bromide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1545 | Q17 | What gene does the drug Clofibrate target? | The drug Clofibrate targets the gene PPARA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clofibrate%" OR LOWER(tradeNames_string) LIKE "%clofibrate%" OR LOWER(drugSynonyms_string) LIKE "%clofibrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2331', 'drugName': 'Clofibrate', 'tradeNames_string': 'Atromid, Atromid-s, Clofibrate', 'drugSynonyms_string': 'AY-61123, Chlorfenisate, Clofibrate, Ethyl p-chlorophenoxyisobutyrate, ICI 28257, ICI-28257, NSC-79389', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319), Myocardial Infarction (EFO_0000612), Myocardial Ischemia (EFO_1001375)', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARA (ENSG00000186951)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1701 | Q17 | What gene does the drug Eltrombopag Olamine target? | The drug Eltrombopag Olamine targets the gene MPL. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eltrombopag olamine%" OR LOWER(tradeNames_string) LIKE "%eltrombopag olamine%" OR LOWER(drugSynonyms_string) LIKE "%eltrombopag olamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2769', 'drugName': 'Eltrombopag Olamine', 'tradeNames_string': 'Promacta, Promacta kit', 'drugSynonyms_string': 'Eltrombopag (as olamine), Eltrombopag compd with 2-aminoethanol (1:2), Eltrombopag olamine, SB-497115-GR', 'linkedDiseasesDrug_string': 'Thrombocytopenia (HP_0001873), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Severe Aplastic Anemia (EFO_0006927), Chronic Hepatitis C Virus Infection (EFO_0004220), Myelodysplastic Syndrome (EFO_0000198)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MPL (ENSG00000117400)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1436 | Q17 | What gene does the drug Regorafenib target? | The drug Regorafenib targets 18 genes: FGFR2, BRAF, FLT4, ABL1, MAPK11, KIT, RET, PDGFRA, RAF1, DDR2, NTRK1, FLT1, FGFR1, KDR, EPHA2, PDGFRB, FRK and TEK. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%regorafenib%" OR LOWER(tradeNames_string) LIKE "%regorafenib%" OR LOWER(drugSynonyms_string) LIKE "%regorafenib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_805', 'drugName': 'Regorafenib', 'tradeNames_string': 'Stivarga', 'drugSynonyms_string': 'BAY 73-4506, BAY 73-4506 monohydrate, BAY-73-4506, BAY-734506, Regorafenib, Regorafenib anhydrous, Regorafenib hydrate, Regorafenib monohydrate', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 18}, {'UUID': 'DrugGeneTargets_v2_808', 'drugName': 'Regorafenib', 'tradeNames_string': 'Stivarga', 'drugSynonyms_string': 'BAY 73-4506, BAY 73-4506 monohydrate, BAY-73-4506, BAY-734506, Regorafenib, Regorafenib anhydrous, Regorafenib hydrate, Regorafenib monohydrate', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 18}, {'UUID': 'DrugGeneTargets_v2_809', 'drugName': 'Regorafenib', 'tradeNames_string': 'Stivarga', 'drugSynonyms_string': 'BAY 73-4506, BAY 73-4506 monohydrate, BAY-73-4506, BAY-734506, Regorafenib, Regorafenib anhydrous, Regorafenib hydrate, Regorafenib monohydrate', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 18}, {'UUID': 'DrugGeneTargets_v2_810', 'drugName': 'Regorafenib', 'tradeNames_string': 'Stivarga', 'drugSynonyms_string': 'BAY 73-4506, BAY 73-4506 monohydrate, BAY-73-4506, BAY-734506, Regorafenib, Regorafenib anhydrous, Regorafenib hydrate, Regorafenib monohydrate', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 18}, {'UUID': 'DrugGeneTargets_v2_812', 'drugName': 'Regorafenib', 'tradeNames_string': 'Stivarga', 'drugSynonyms_string': 'BAY 73-4506, BAY 73-4506 monohydrate, BAY-73-4506, BAY-734506, Regorafenib, Regorafenib anhydrous, Regorafenib hydrate, Regorafenib monohydrate', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 18}, {'UUID': 'DrugGeneTargets_v2_813', 'drugName': 'Regorafenib', 'tradeNames_string': 'Stivarga', 'drugSynonyms_string': 'BAY 73-4506, BAY 73-4506 monohydrate, BAY-73-4506, BAY-734506, Regorafenib, Regorafenib anhydrous, Regorafenib hydrate, Regorafenib monohydrate', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 18}, {'UUID': 'DrugGeneTargets_v2_814', 'drugName': 'Regorafenib', 'tradeNames_string': 'Stivarga', 'drugSynonyms_string': 'BAY 73-4506, BAY 73-4506 monohydrate, BAY-73-4506, BAY-734506, Regorafenib, Regorafenib anhydrous, Regorafenib hydrate, Regorafenib monohydrate', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 18}, {'UUID': 'DrugGeneTargets_v2_807', 'drugName': 'Regorafenib', 'tradeNames_string': 'Stivarga', 'drugSynonyms_string': 'BAY 73-4506, BAY 73-4506 monohydrate, BAY-73-4506, BAY-734506, Regorafenib, Regorafenib anhydrous, Regorafenib hydrate, Regorafenib monohydrate', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 18}, {'UUID': 'DrugGeneTargets_v2_803', 'drugName': 'Regorafenib', 'tradeNames_string': 'Stivarga', 'drugSynonyms_string': 'BAY 73-4506, BAY 73-4506 monohydrate, BAY-73-4506, BAY-734506, Regorafenib, Regorafenib anhydrous, Regorafenib hydrate, Regorafenib monohydrate', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 18}, {'UUID': 'DrugGeneTargets_v2_801', 'drugName': 'Regorafenib', 'tradeNames_string': 'Stivarga', 'drugSynonyms_string': 'BAY 73-4506, BAY 73-4506 monohydrate, BAY-73-4506, BAY-734506, Regorafenib, Regorafenib anhydrous, Regorafenib hydrate, Regorafenib monohydrate', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 18}, {'UUID': 'DrugGeneTargets_v2_800', 'drugName': 'Regorafenib', 'tradeNames_string': 'Stivarga', 'drugSynonyms_string': 'BAY 73-4506, BAY 73-4506 monohydrate, BAY-73-4506, BAY-734506, Regorafenib, Regorafenib anhydrous, Regorafenib hydrate, Regorafenib monohydrate', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 18}, {'UUID': 'DrugGeneTargets_v2_811', 'drugName': 'Regorafenib', 'tradeNames_string': 'Stivarga', 'drugSynonyms_string': 'BAY 73-4506, BAY 73-4506 monohydrate, BAY-73-4506, BAY-734506, Regorafenib, Regorafenib anhydrous, Regorafenib hydrate, Regorafenib monohydrate', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 18}, {'UUID': 'DrugGeneTargets_v2_806', 'drugName': 'Regorafenib', 'tradeNames_string': 'Stivarga', 'drugSynonyms_string': 'BAY 73-4506, BAY 73-4506 monohydrate, BAY-73-4506, BAY-734506, Regorafenib, Regorafenib anhydrous, Regorafenib hydrate, Regorafenib monohydrate', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 18}, {'UUID': 'DrugGeneTargets_v2_804', 'drugName': 'Regorafenib', 'tradeNames_string': 'Stivarga', 'drugSynonyms_string': 'BAY 73-4506, BAY 73-4506 monohydrate, BAY-73-4506, BAY-734506, Regorafenib, Regorafenib anhydrous, Regorafenib hydrate, Regorafenib monohydrate', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 18}, {'UUID': 'DrugGeneTargets_v2_802', 'drugName': 'Regorafenib', 'tradeNames_string': 'Stivarga', 'drugSynonyms_string': 'BAY 73-4506, BAY 73-4506 monohydrate, BAY-73-4506, BAY-734506, Regorafenib, Regorafenib anhydrous, Regorafenib hydrate, Regorafenib monohydrate', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 18}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.915 | Q17 | What gene does the drug Bimekizumab target? | The drug Bimekizumab targets 2 genes: IL17F and IL17A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bimekizumab%" OR LOWER(tradeNames_string) LIKE "%bimekizumab%" OR LOWER(drugSynonyms_string) LIKE "%bimekizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_305', 'drugName': 'Bimekizumab', 'tradeNames_string': '', 'drugSynonyms_string': 'Bimekizumab, UCB-4940, UCB4940, Ucb4940', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Ankylosing Spondylitis (EFO_0003898), Psoriatic Arthritis (EFO_0003778), Rheumatoid Arthritis (EFO_0000685), Hidradenitis Suppurativa (EFO_1000710), Immune System Disease (EFO_0000540)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IL17F (ENSG00000112116), IL17A (ENSG00000112115)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_306', 'drugName': 'Bimekizumab', 'tradeNames_string': '', 'drugSynonyms_string': 'Bimekizumab, UCB-4940, UCB4940, Ucb4940', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Ankylosing Spondylitis (EFO_0003898), Psoriatic Arthritis (EFO_0003778), Rheumatoid Arthritis (EFO_0000685), Hidradenitis Suppurativa (EFO_1000710), Immune System Disease (EFO_0000540)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IL17F (ENSG00000112116), IL17A (ENSG00000112115)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.310 | Q17 | What gene does the drug Dilevalol Hydrochloride target? | The drug Dilevalol Hydrochloride targets 3 genes: ADRB3, ADRB1 and ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dilevalol hydrochloride%" OR LOWER(tradeNames_string) LIKE "%dilevalol hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%dilevalol hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3364', 'drugName': 'Dilevalol Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Dilevalol hcl, Dilevalol hydrochloride, SCH 19927, SCH-19927', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3365', 'drugName': 'Dilevalol Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Dilevalol hcl, Dilevalol hydrochloride, SCH 19927, SCH-19927', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1257 | Q17 | What gene does the drug Bepranemab target? | The drug Bepranemab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MAPT. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bepranemab%" OR LOWER(tradeNames_string) LIKE "%bepranemab%" OR LOWER(drugSynonyms_string) LIKE "%bepranemab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3673', 'drugName': 'Bepranemab', 'tradeNames_string': '', 'drugSynonyms_string': 'Bepranemab, UCB-0107, UCB0107, Ucb0107', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Progressive Supranuclear Palsy (MONDO_0019037)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAPT (ENSG00000186868)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1409 | Q17 | What gene does the drug Cg250 177Lu target? | The drug Cg250 177Lu is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CA9. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cg250 177lu%" OR LOWER(tradeNames_string) LIKE "%cg250 177lu%" OR LOWER(drugSynonyms_string) LIKE "%cg250 177lu%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6064', 'drugName': 'Cg250 177Lu', 'tradeNames_string': '', 'drugSynonyms_string': 'CG250, Cg250 (177lu), Cg250 177lu', 'linkedDiseasesDrug_string': 'Renal Cell Carcinoma (EFO_0000681)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CA9 (ENSG00000107159)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.618 | Q17 | What gene does the drug Trimethadione target? | The drug Trimethadione targets 3 genes: CACNA1G, CACNA1I and CACNA1H. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trimethadione%" OR LOWER(tradeNames_string) LIKE "%trimethadione%" OR LOWER(drugSynonyms_string) LIKE "%trimethadione%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4418', 'drugName': 'Trimethadione', 'tradeNames_string': 'Tridione', 'drugSynonyms_string': 'A 2297, Absentol, Epidione, J2.519D, Minoaleviatin, NSC-15799, NSC-169503, Tridone, Trimethadione, Trimethadionum, Troxidone', 'linkedDiseasesDrug_string': 'Epilepsy (EFO_0000474)', 'yearOfFirstApproval': 1946, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA1G (ENSG00000006283), CACNA1I (ENSG00000100346)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1479 | Q17 | What gene does the drug Isotretinoin target? | The drug Isotretinoin targets 3 genes: RARB, RARA and RARG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%isotretinoin%" OR LOWER(tradeNames_string) LIKE "%isotretinoin%" OR LOWER(drugSynonyms_string) LIKE "%isotretinoin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3116', 'drugName': 'Isotretinoin', 'tradeNames_string': 'Absorica, Absorica ld, Accutane, Amnesteem, Claravis, Isotrex, Myorisan, Roaccutane, Sotret, Zenatane', 'drugSynonyms_string': '13 Cis-Retinoic Acid, 13-cis-retinoic acid, Isotretinoin, NSC-758156, PAT-001, RO 4-3780, RO-4-3780, RO-43780, Retinoic acid 13-cis-form, Retinoic acid, 13-cis-, Vitamin a acid, 13-cis', 'linkedDiseasesDrug_string': "Neuroblastoma (EFO_0000621), Multiple Myeloma (EFO_0001378), Alzheimer Disease (MONDO_0004975), Medulloblastoma (EFO_0002939), Infection (EFO_0000544), Rosacea (EFO_1000760), Mixed Glioma (MONDO_0003268), Covid-19 (MONDO_0100096), Oligodendroglioma (EFO_0000632), Azoospermia (EFO_0000279), Klinefelter'S Syndrome (EFO_1001006), Burkitts Lymphoma (EFO_0000309), Myelodysplastic Syndrome (EFO_0000198), Focal Segmental Glomerulosclerosis (EFO_0004236), Chronic Myelogenous Leukemia (EFO_0000339), Juvenile Myelomonocytic Leukemia (EFO_1000309), Acute Promyelocytic Leukemia (EFO_0000224), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Tinea Pedis (EFO_0007512), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Myeloid Leukemia (EFO_0000222), Wilms Tumor (MONDO_0006058), Mycosis Fungoides (EFO_1001051), Acne (EFO_0003894), Emphysema (EFO_0000464), Diffuse Large B-Cell Lymphoma (EFO_0000403), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Ganglioneuroblastoma (EFO_0000502), Actinic Keratosis (EFO_0002496), Lymphoblastic Lymphoma (MONDO_0000873), Renal Cell Carcinoma (EFO_0000681), Hiv-1 Infection (EFO_0000180), Brain Neoplasm (EFO_0003833), Dysplasia Of Cervix (EFO_1000910), Hodgkins Lymphoma (EFO_0000183), Cervical Cancer (MONDO_0002974), Head And Neck Malignant Neoplasia (EFO_0006859), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Kidney Cancer (MONDO_0002367), Ichthyosis (MONDO_0019269), Epidermolysis Bullosa (EFO_1000690), Glioblastoma Multiforme (EFO_0000519)", 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'RARG (ENSG00000172819), RARB (ENSG00000077092), RARA (ENSG00000131759)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.250 | Q17 | What gene does the drug Nadolol target? | The drug Nadolol targets 2 genes: ADRB1 and ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nadolol%" OR LOWER(tradeNames_string) LIKE "%nadolol%" OR LOWER(drugSynonyms_string) LIKE "%nadolol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_424', 'drugName': 'Nadolol', 'tradeNames_string': 'Corgard, Nadolol, Solgol', 'drugSynonyms_string': 'NSC-758430, Nadolol, SQ 11725, SQ-11725', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Smoking Cessation (EFO_0004319), Angina Pectoris (EFO_0003913), Stroke (EFO_0000712), Hypertension (EFO_0000537), Hemangioma (EFO_1000635), Cardiovascular Disease (EFO_0000319), Myocardial Infarction (EFO_0000612)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_425', 'drugName': 'Nadolol', 'tradeNames_string': 'Corgard, Nadolol, Solgol', 'drugSynonyms_string': 'NSC-758430, Nadolol, SQ 11725, SQ-11725', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Smoking Cessation (EFO_0004319), Angina Pectoris (EFO_0003913), Stroke (EFO_0000712), Hypertension (EFO_0000537), Hemangioma (EFO_1000635), Cardiovascular Disease (EFO_0000319), Myocardial Infarction (EFO_0000612)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.734 | Q17 | What gene does the drug Insulin Susp Isophane Beef target? | The drug Insulin Susp Isophane Beef targets the gene INSR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%insulin susp isophane beef%" OR LOWER(tradeNames_string) LIKE "%insulin susp isophane beef%" OR LOWER(drugSynonyms_string) LIKE "%insulin susp isophane beef%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5706', 'drugName': 'Insulin Susp Isophane Beef', 'tradeNames_string': 'Nph insulin', 'drugSynonyms_string': 'Insulin susp isophane beef', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148), Gestational Diabetes (EFO_0004593), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1693', 'drugName': 'Insulin Susp Isophane Beef/Pork', 'tradeNames_string': 'Nph iletin i (beef-pork)', 'drugSynonyms_string': 'Insulin susp isophane beef/pork', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1966, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.311 | Q17 | What gene does the drug Alefacept target? | The drug Alefacept targets the gene CD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alefacept%" OR LOWER(tradeNames_string) LIKE "%alefacept%" OR LOWER(drugSynonyms_string) LIKE "%alefacept%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4052', 'drugName': 'Alefacept', 'tradeNames_string': 'Amevive', 'drugSynonyms_string': 'Alefacept, BG-9273, BG-9712, BG9273, BG9712, Human lfa-3igg fusion protein, LFA-3CD2, LFA-3TIP, LFA3TIP', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Pustulosis Palmaris Et Plantaris (MONDO_0015597), Lichen Planus (EFO_1000726), Psoriatic Arthritis (EFO_0003778), Lymphoma (EFO_0000574), Kidney Failure (EFO_1002048), Aplastic Anemia (HP_0001915), Type 1 Diabetes Mellitus (MONDO_0005147), Immune System Disease (EFO_0000540)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD2 (ENSG00000116824)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.236 | Q17 | What gene does the drug Bupropion Hydrobromide target? | The drug Bupropion Hydrobromide targets 2 genes: SLC6A2 and SLC6A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bupropion hydrobromide%" OR LOWER(tradeNames_string) LIKE "%bupropion hydrobromide%" OR LOWER(drugSynonyms_string) LIKE "%bupropion hydrobromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1806', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_string': 'Aplenzin', 'drugSynonyms_string': 'BVF-033, Bupropion hbr, Bupropion hydrobromide', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1807', 'drugName': 'Bupropion Hydrobromide', 'tradeNames_string': 'Aplenzin', 'drugSynonyms_string': 'BVF-033, Bupropion hbr, Bupropion hydrobromide', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.72 | Q17 | What gene does the drug Apomorphine target? | The drug Apomorphine targets 3 genes: DRD3, DRD4 and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%apomorphine%" OR LOWER(tradeNames_string) LIKE "%apomorphine%" OR LOWER(drugSynonyms_string) LIKE "%apomorphine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3259', 'drugName': 'Apomorphine', 'tradeNames_string': '', 'drugSynonyms_string': '6a.beta.-aporphine-10,11-diol, APL-130277, Apomorphine, Apomorphinum, VR-040, VR040', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Erectile Dysfunction (EFO_0004234), Neoplasm (EFO_0000616), Parkinson Disease (MONDO_0005180), Brain Injury (MONDO_0043510), Hallucinations (HP_0000738), Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3300', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_string': 'Apo-go, Apo-go pen, Apo-go pfs, Apokyn, Apomorph hcl, Britaject, Bromophin, Dacepton, Diagesil, Diamorph hcl, Diamorph roche, Diamorph,cocaine,chlorpromazine, Diaphine, Euphorin, Kynmobi, Uprima', 'drugSynonyms_string': 'Apokinon, Apomine, Apomorphine HCl, Apomorphine hcl, Apomorphine hydrochloride, Apomorphine hydrochloride hemihydrate, Apomorphine hydrochloride hydrate, Apomorphinum muriaticum, Diamorphine hydrochloride , Ixense, Kw-6500, NSC-11442, NSC-755875, Taluvian', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Osteoporosis (EFO_0003882), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.896 | Q17 | What gene does the drug Bupropion Hydrochloride target? | The drug Bupropion Hydrochloride targets 2 genes: SLC6A2 and SLC6A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bupropion hydrochloride%" OR LOWER(tradeNames_string) LIKE "%bupropion hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%bupropion hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_771', 'drugName': 'Bupropion Hydrochloride', 'tradeNames_string': 'Bupropion hydrochloride, Forfivo xl, Wellbutrin, Wellbutrin 100, Wellbutrin 75, Wellbutrin sr, Wellbutrin xl, Zyban', 'drugSynonyms_string': 'Amfebutamone hydrochloride, BW 323, BW-323, BW323, Bupropion HCl, Bupropion hcl, Bupropion hydrochloride, Mysimba, NSC-315851', 'linkedDiseasesDrug_string': 'Smoking Cessation (EFO_0004319), Unipolar Depression (EFO_0003761), Lung Cancer (MONDO_0008903), Bipolar I Disorder (EFO_0009963), Nicotine Dependence (EFO_0003768), Mood Disorder (EFO_0004247), Obesity (EFO_0001073), Wilson Disease (MONDO_0010200), Major Depressive Disorder (MONDO_0002009), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Eating Disorder (EFO_0005203), Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_772', 'drugName': 'Bupropion Hydrochloride', 'tradeNames_string': 'Bupropion hydrochloride, Forfivo xl, Wellbutrin, Wellbutrin 100, Wellbutrin 75, Wellbutrin sr, Wellbutrin xl, Zyban', 'drugSynonyms_string': 'Amfebutamone hydrochloride, BW 323, BW-323, BW323, Bupropion HCl, Bupropion hcl, Bupropion hydrochloride, Mysimba, NSC-315851', 'linkedDiseasesDrug_string': 'Smoking Cessation (EFO_0004319), Unipolar Depression (EFO_0003761), Lung Cancer (MONDO_0008903), Bipolar I Disorder (EFO_0009963), Nicotine Dependence (EFO_0003768), Mood Disorder (EFO_0004247), Obesity (EFO_0001073), Wilson Disease (MONDO_0010200), Major Depressive Disorder (MONDO_0002009), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Eating Disorder (EFO_0005203), Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1754 | Q17 | What gene does the drug Pamrevlumab target? | The drug Pamrevlumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CCN2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pamrevlumab%" OR LOWER(tradeNames_string) LIKE "%pamrevlumab%" OR LOWER(drugSynonyms_string) LIKE "%pamrevlumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_624', 'drugName': 'Pamrevlumab', 'tradeNames_string': '', 'drugSynonyms_string': 'FG-3019, Pamrevlumab', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Pancreatic Carcinoma (EFO_0002618), Chronic Hepatitis B Virus Infection (EFO_0004239), Duchenne Muscular Dystrophy (MONDO_0010679), Covid-19 (MONDO_0100096), Idiopathic Pulmonary Fibrosis (EFO_0000768), Focal Segmental Glomerulosclerosis (EFO_0004236)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CCN2 (ENSG00000118523)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.712 | Q17 | What gene does the drug Midazolam target? | The drug Midazolam targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%midazolam%" OR LOWER(tradeNames_string) LIKE "%midazolam%" OR LOWER(drugSynonyms_string) LIKE "%midazolam%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4008', 'drugName': 'Midazolam Hydrochloride', 'tradeNames_string': 'Buccolam, Dormicum, Hypnovel, Midazolam hydrochloride, Midazolam hydrochloride (autoinjector), Midazolam hydrochloride preservative free, Midozalam hydrochloride, Rocam, Seizalam, Versed', 'drugSynonyms_string': 'Midazolam hcl, Midazolam hydrochloride, Midazolam hydrochloride civ, NSC-751451, RO 21-3981/003, RO-213981001, Ro-213981-003, SHP-615, SHP615', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Type 2 Diabetes Mellitus (MONDO_0005148), Nervous System Disease (EFO_0000618), Atopic Eczema (EFO_0000274), Tuberculosis (MONDO_0018076), Polyp (EFO_0000662), Major Depressive Disorder (MONDO_0002009), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Amnesia (EFO_1001454), Status Epilepticus (EFO_0008526)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_2188', 'drugName': 'Midazolam', 'tradeNames_string': 'Midazolam in 0.8% sodium chloride, Midazolam in 0.9% sodium chloride, Nayzilam', 'drugSynonyms_string': 'Midazolam, Midazolam civ, USL-261, USL261', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Postmenopausal Osteoporosis (EFO_0003854), Infection (EFO_0000544), Nervous System Disease (EFO_0000618), Ischemic Stroke (HP_0002140), Atopic Eczema (EFO_0000274), Spinal Muscular Atrophy (EFO_0008525), Hypertension (EFO_0000537), Neuropathic Pain (EFO_0005762), Bone Fracture (EFO_0003931), Neck Pain (HP_0030833), Obsessive-Compulsive Disorder (EFO_0004242), Anemia (Phenotype) (EFO_0004272), Borderline Personality Disorder (HP_0012076), Inguinal Hernia (HP_0000023), Sickle Cell Anemia (MONDO_0011382), Aspergillosis (EFO_0007157), Respiratory Failure (EFO_0009686), Atherosclerosis (EFO_0003914), Schizophrenia (MONDO_0005090), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Hemorrhage (MP_0001914), Pain (EFO_0003843), Obesity (EFO_0001073), Pulmonary Tuberculosis (EFO_1000049), Gastrointestinal Stromal Tumor (MONDO_0011719), Amnesia (EFO_1001454), Hypotension (EFO_0005251), Status Epilepticus (EFO_0008526), Cataract (MONDO_0005129), Non-Alcoholic Steatohepatitis (EFO_1001249), Dementia (HP_0000726), Anxiety (EFO_0005230), Acute Myeloid Leukemia (EFO_0000222), Endometriosis (EFO_0001065), Mitochondrial Disease (MONDO_0044970), Fibrodysplasia Ossificans Progressiva (MONDO_0007606), Seizure (HP_0001250), Treatment Resistant Depression (EFO_0009854), Delirium (EFO_0009267), Chronic Hepatitis C Virus Infection (EFO_0004220), Influenza (EFO_0007328), Fluoride Poisoning (EFO_1001328), Urogenital Neoplasm (EFO_0003863), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Low Back Pain (HP_0003419), Multiple Bone Fractures (EFO_0009513), Alzheimer Disease (MONDO_0004975), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Psoriasis Vulgaris (EFO_1001494), Breast Neoplasm (EFO_0003869), Post-Traumatic Stress Disorder (EFO_0001358), Breast Cancer (MONDO_0007254), Chronic Hepatitis B Virus Infection (EFO_0004239), Cardiovascular Disease (EFO_0000319), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Epilepsy (EFO_0000474), Renal Insufficiency (HP_0000083), Aggressive Behavior (EFO_0003015), Drug Dependence (EFO_0003890), Respiratory Syncytial Virus Infection (EFO_1001413), Mesothelioma (EFO_0000588), Infertility (EFO_0000545), Polyp (EFO_0000662), Brain Injury (MONDO_0043510), Depressive Disorder (MONDO_0002050), Neoplasm (EFO_0000616), Heart Failure (EFO_0003144), Chronic Pain (HP_0012532), Tuberculosis (MONDO_0018076), Skin Disease (EFO_0000701), Major Depressive Disorder (MONDO_0002009), Type 2 Diabetes Mellitus (MONDO_0005148), Breech Presentation (HP_0001623), Infectious Disease (EFO_0005741), Cough (HP_0012735), Covid-19 (MONDO_0100096), Metastatic Melanoma (EFO_0002617), Post Operative Nausea And Vomiting (EFO_0004888), Injury (EFO_0000546), Ulcerative Colitis (EFO_0000729), Malaria (EFO_0001068), Hepatitis C Virus Infection (EFO_0003047), Prostate Adenocarcinoma (EFO_0000673), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Nicotine Dependence (EFO_0003768), Septic Shock (EFO_0006834), Schizoaffective Disorder (EFO_0005411), Parkinson Disease (MONDO_0005180), Cocaine Dependence (EFO_0002610), Pruritus (HP_0000989), Suicidal Ideation (EFO_0004320), Sepsis (HP_0100806), Subarachnoid Hemorrhage (EFO_0000713), Bipolar Disorder (MONDO_0004985), Rheumatoid Arthritis (EFO_0000685), Recurrent Tonsillitis (HP_0011110), Amyotrophic Lateral Sclerosis (MONDO_0004976), Fatigue (HP_0012378), Cirrhosis Of Liver (EFO_0001422)", 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1383 | Q17 | What gene does the drug Fomepizole target? | The drug Fomepizole targets 3 genes: ADH1A, ADH1C and ADH1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fomepizole%" OR LOWER(tradeNames_string) LIKE "%fomepizole%" OR LOWER(drugSynonyms_string) LIKE "%fomepizole%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1663', 'drugName': 'Fomepizole', 'tradeNames_string': 'Antizol, Fomepizole', 'drugSynonyms_string': '4-MP, 4-methylpyrazole, Fomepizole, NSC-760365', 'linkedDiseasesDrug_string': 'Age-Related Macular Degeneration (EFO_0001365)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADH1A (ENSG00000187758), ADH1B (ENSG00000196616), ADH1C (ENSG00000248144)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1329 | Q17 | What gene does the drug Moexipril Hydrochloride target? | The drug Moexipril Hydrochloride targets the gene ACE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%moexipril hydrochloride%" OR LOWER(tradeNames_string) LIKE "%moexipril hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%moexipril hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_517', 'drugName': 'Moexipril Hydrochloride', 'tradeNames_string': 'Moexipril hydrochloride, Perdix, Univasc', 'drugSynonyms_string': 'CI 925, CI-925, Moexipril hcl, Moexipril hydrochloride, RS-10085-197, SPM 925, SPM-925', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.624 | Q17 | What gene does the drug Valbenazine Tosylate target? | The drug Valbenazine Tosylate targets the gene SLC18A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%valbenazine tosylate%" OR LOWER(tradeNames_string) LIKE "%valbenazine tosylate%" OR LOWER(drugSynonyms_string) LIKE "%valbenazine tosylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5423', 'drugName': 'Valbenazine Tosylate', 'tradeNames_string': 'Ingrezza', 'drugSynonyms_string': 'NBI-98854, Valbenazine ditosylate, Valbenazine tosilate, Valbenazine tosylate', 'linkedDiseasesDrug_string': 'Movement Disorder (EFO_0004280)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1464 | Q17 | What gene does the drug Inclisiran target? | The drug Inclisiran targets the gene PCSK9. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%inclisiran%" OR LOWER(tradeNames_string) LIKE "%inclisiran%" OR LOWER(drugSynonyms_string) LIKE "%inclisiran%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_859', 'drugName': 'Inclisiran', 'tradeNames_string': '', 'drugSynonyms_string': 'ALN-60212, ALN-PCSSC, ALN-PSCsc, Inclisiran, Leqvio', 'linkedDiseasesDrug_string': 'Hyperlipidemia (MONDO_0021187), Coronary Artery Disease (EFO_0001645), Familial Hypercholesterolemia (EFO_0004911), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Kidney Disease (EFO_0003086), Acute Coronary Syndrome (EFO_0005672), Homozygous Familial Hypercholesterolemia (MONDO_0018328)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PCSK9 (ENSG00000169174)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4738', 'drugName': 'Inclisiran Sodium', 'tradeNames_string': 'Leqvio', 'drugSynonyms_string': 'Inclisiran sodium, Leqvio sodium', 'linkedDiseasesDrug_string': 'Atherosclerosis (EFO_0003914), Familial Hypercholesterolemia (EFO_0004911)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PCSK9 (ENSG00000169174)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1556 | Q17 | What gene does the drug Mipomersen Sodium target? | The drug Mipomersen Sodium targets the gene APOB. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mipomersen sodium%" OR LOWER(tradeNames_string) LIKE "%mipomersen sodium%" OR LOWER(drugSynonyms_string) LIKE "%mipomersen sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3718', 'drugName': 'Mipomersen Sodium', 'tradeNames_string': 'Kynamro', 'drugSynonyms_string': 'ISIS 301012, ISIS-301012, Mipomersen sodium, Mipomersen sodium salt', 'linkedDiseasesDrug_string': 'Familial Hypercholesterolemia (EFO_0004911), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'APOB (ENSG00000084674)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.708 | Q17 | What gene does the drug Calcitonin target? | The drug Calcitonin targets the gene CALCR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%calcitonin%" OR LOWER(tradeNames_string) LIKE "%calcitonin%" OR LOWER(drugSynonyms_string) LIKE "%calcitonin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5401', 'drugName': 'Calcitonin Salmon', 'tradeNames_string': 'Calcimar, Calcitonin-salmon, Miacalcin', 'drugSynonyms_string': 'Calcitonin salmon', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Postmenopausal Osteoporosis (EFO_0003854), Menopause (EFO_0003922), Osteitis Deformans (EFO_0004261), Hypercalcemia (HP_0003072)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CALCR (ENSG00000004948)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_134', 'drugName': 'Calcitonin', 'tradeNames_string': 'Calcimar, Calcitare, Calsynar, Cibacalcin, Forcaltonin, Fortical, Miacalcic', 'drugSynonyms_string': 'Calcitonin, Calcitonin, unspecified, Throcalcitonin', 'linkedDiseasesDrug_string': 'Calcinosis (MONDO_0002123), Giant Cell Reparative Granuloma (EFO_1000950), Postmenopausal Osteoporosis (EFO_0003854)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CALCR (ENSG00000004948)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1951', 'drugName': 'Calcitonin Human', 'tradeNames_string': 'Cibacalcin', 'drugSynonyms_string': 'Calcitonin (human synthetic), Calcitonin human', 'linkedDiseasesDrug_string': 'Parathyroid Disease (EFO_0005754)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CALCR (ENSG00000004948)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4748', 'drugName': 'Calcitonin Salmon Recombinant', 'tradeNames_string': 'Fortical', 'drugSynonyms_string': 'Calcitonin (salmon synthetic), Calcitonin salmon recombinant', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Osteopenia (HP_0000938), Parathyroid Disease (EFO_0005754), Postmenopausal Osteoporosis (EFO_0003854)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CALCR (ENSG00000004948)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1928 | Q17 | What gene does the drug Rapacuronium Bromide target? | The drug Rapacuronium Bromide targets 5 genes: CHRNB1, CHRNA1, CHRND, CHRNE and CHRNG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rapacuronium bromide%" OR LOWER(tradeNames_string) LIKE "%rapacuronium bromide%" OR LOWER(drugSynonyms_string) LIKE "%rapacuronium bromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5464', 'drugName': 'Rapacuronium Bromide', 'tradeNames_string': 'Raplon', 'drugSynonyms_string': 'ORG 9487, ORG-9487, Rapacuronium bromide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.614 | Q17 | What gene does the drug Pentostatin target? | The drug Pentostatin targets the gene ADA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pentostatin%" OR LOWER(tradeNames_string) LIKE "%pentostatin%" OR LOWER(drugSynonyms_string) LIKE "%pentostatin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_251', 'drugName': 'Pentostatin', 'tradeNames_string': 'Nipent, Pentostatin', 'drugSynonyms_string': 'CI-825, Deoxycoformycin, NSC-218321, Nipent, PD 81565, PD-81565, Pentostatin, YK-176', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Graft Versus Host Disease (MONDO_0013730), Sickle Cell Anemia (MONDO_0011382), Kidney Cancer (MONDO_0002367), Lymphoma (EFO_0000574), Anemia (MONDO_0002280), Acute Graft Vs. Host Disease (EFO_0004599), Hairy Cell Leukemia (EFO_1000956)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADA (ENSG00000196839)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.372 | Q17 | What gene does the drug Epratuzumab 90Y target? | The drug Epratuzumab 90Y is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD22. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%epratuzumab 90y%" OR LOWER(tradeNames_string) LIKE "%epratuzumab 90y%" OR LOWER(drugSynonyms_string) LIKE "%epratuzumab 90y%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1852', 'drugName': 'Epratuzumab 90Y', 'tradeNames_string': 'Lymphocide', 'drugSynonyms_string': 'AMG-412, Epratuzumab 90y, HLL2', 'linkedDiseasesDrug_string': 'B-Cell Non-Hodgkins Lymphoma (EFO_1001938)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD22 (ENSG00000012124)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1756 | Q17 | What gene does the drug Cabazitaxel target? | The drug Cabazitaxel targets 15 genes: TUBB, TUBA4A, TUBA3E, TUBB3, TUBB4B, TUBB2A, TUBA1A, TUBA1C, TUBB1, TUBB2B, TUBB8, TUBB6, TUBB4A, TUBA3C and TUBA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cabazitaxel%" OR LOWER(tradeNames_string) LIKE "%cabazitaxel%" OR LOWER(drugSynonyms_string) LIKE "%cabazitaxel%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_762', 'drugName': 'Cabazitaxel', 'tradeNames_string': 'Jevtana, Jevtana kit', 'drugSynonyms_string': 'Cabazitaxel, Cabazitaxel acetonate, Jevtana, NSC-761432, TXD 258, TXD-258, XRP 6258, XRP-6258', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Central Nervous System Cancer (EFO_0000326), Urothelial Carcinoma (EFO_0008528), Colorectal Carcinoma (EFO_1001951), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Prostate Adenocarcinoma (EFO_0000673), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Penile Neoplasm (EFO_1001094), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Dedifferentiated Liposarcoma (EFO_0003085), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Brain Cancer (MONDO_0001657), Head And Neck Malignant Neoplasia (EFO_0006859), Neoplasm (EFO_0000616), Testicular Carcinoma (EFO_0005088), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Cortex Carcinoma (EFO_1000796), Transitional Cell Carcinoma (EFO_1000601), Metastatic Prostate Cancer (EFO_0000196), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 15}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1669 | Q17 | What gene does the drug Ertumaxomab target? | The drug Ertumaxomab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: ERBB2 and CD3E | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ertumaxomab%" OR LOWER(tradeNames_string) LIKE "%ertumaxomab%" OR LOWER(drugSynonyms_string) LIKE "%ertumaxomab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2144', 'drugName': 'Ertumaxomab', 'tradeNames_string': 'Rexomun', 'drugSynonyms_string': 'Ertumaxomab', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), CD3E (ENSG00000198851)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2145', 'drugName': 'Ertumaxomab', 'tradeNames_string': 'Rexomun', 'drugSynonyms_string': 'Ertumaxomab', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), CD3E (ENSG00000198851)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.533 | Q17 | What gene does the drug Fosinopril Sodium target? | The drug Fosinopril Sodium targets the gene ACE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fosinopril sodium%" OR LOWER(tradeNames_string) LIKE "%fosinopril sodium%" OR LOWER(drugSynonyms_string) LIKE "%fosinopril sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2506', 'drugName': 'Fosinopril Sodium', 'tradeNames_string': 'Fosinopril sodium, Fositens, Fozitec, Monopril, Staril', 'drugSynonyms_string': 'Fosenopril sodium, Fosinopril sodium, Fosinopril sodium salt, SQ 28555, SQ-28555', 'linkedDiseasesDrug_string': 'Heart Failure (EFO_0003144), Hypertension (EFO_0000537)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1821 | Q17 | What gene does the drug Balsalazide Disodium target? | The drug Balsalazide Disodium targets 4 genes: PTGS2, PPARG, ALOX5 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%balsalazide disodium%" OR LOWER(tradeNames_string) LIKE "%balsalazide disodium%" OR LOWER(drugSynonyms_string) LIKE "%balsalazide disodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1296', 'drugName': 'Balsalazide Disodium', 'tradeNames_string': 'Balsalazide disodium, Colazal, Colazide, Giazo', 'drugSynonyms_string': 'BX-661A, BX661A, Balsalazide disodium, Balsalazide disodium anhydrous, Balsalazide disodium dihydrate, Balsalazide disodium salt dihydrate, Balsalazide sodium, Balsalazine, NSC-760046', 'linkedDiseasesDrug_string': 'Ulcerative Colitis (EFO_0000729)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_1297', 'drugName': 'Balsalazide Disodium', 'tradeNames_string': 'Balsalazide disodium, Colazal, Colazide, Giazo', 'drugSynonyms_string': 'BX-661A, BX661A, Balsalazide disodium, Balsalazide disodium anhydrous, Balsalazide disodium dihydrate, Balsalazide disodium salt dihydrate, Balsalazide sodium, Balsalazine, NSC-760046', 'linkedDiseasesDrug_string': 'Ulcerative Colitis (EFO_0000729)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_1298', 'drugName': 'Balsalazide Disodium', 'tradeNames_string': 'Balsalazide disodium, Colazal, Colazide, Giazo', 'drugSynonyms_string': 'BX-661A, BX661A, Balsalazide disodium, Balsalazide disodium anhydrous, Balsalazide disodium dihydrate, Balsalazide disodium salt dihydrate, Balsalazide sodium, Balsalazine, NSC-760046', 'linkedDiseasesDrug_string': 'Ulcerative Colitis (EFO_0000729)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1442 | Q17 | What gene does the drug Carbinoxamine Maleate target? | The drug Carbinoxamine Maleate targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%carbinoxamine maleate%" OR LOWER(tradeNames_string) LIKE "%carbinoxamine maleate%" OR LOWER(drugSynonyms_string) LIKE "%carbinoxamine maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4593', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_string': 'Carbinoxamine maleate, Clistin, Davenol, Karbinal er', 'drugSynonyms_string': 'Carbinoxamine maleate, NSC-62362', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Angioedema (EFO_0005532), Vasomotor Rhinitis (EFO_0007533), Urticaria (EFO_0005531)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.302 | Q17 | What gene does the drug Tizanidine Hydrochloride target? | The drug Tizanidine Hydrochloride targets 3 genes: ADRA2A, ADRA2C and ADRA2B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tizanidine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%tizanidine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%tizanidine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5012', 'drugName': 'Tizanidine Hydrochloride', 'tradeNames_string': 'Sirdalud, Sirdalud mr, Tizanidine hydrochloride, Zanaflex', 'drugSynonyms_string': 'AN-021, AN021, DS 103-282, DS-103-282, Tizanidine (as hydrochloride), Tizanidine hcl, Tizanidine hydrochloride', 'linkedDiseasesDrug_string': 'Migraine With Aura (MONDO_0005475), Migraine Without Aura (MONDO_0100431), Radiculopathy (MONDO_0002959), Spasticity (HP_0001257), Brain Injury (MONDO_0043510)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1016 | Q17 | What gene does the drug Methylprednisolone Sodium Succinate target? | The drug Methylprednisolone Sodium Succinate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methylprednisolone sodium succinate%" OR LOWER(tradeNames_string) LIKE "%methylprednisolone sodium succinate%" OR LOWER(drugSynonyms_string) LIKE "%methylprednisolone sodium succinate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5705', 'drugName': 'Methylprednisolone Sodium Succinate', 'tradeNames_string': 'A-methapred, Methylprednisolone, Methylprednisolone sodium succinate, Min-i-mix, Solu-medrol, Solu-medrone, Urbasone', 'drugSynonyms_string': 'Methylprednisolone 21-succinate sodium salt, Methylprednisolone sodium succinate, NSC-48989', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Pneumonia (EFO_0003106), Multiple Sclerosis (MONDO_0005301), Drug-Induced Liver Injury (EFO_0004228), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Graft Versus Host Disease (MONDO_0013730), Glomerulonephritis (MONDO_0002462), Iga Glomerulonephritis (EFO_0004194), Systemic Lupus Erythematosus (MONDO_0007915), Mast-Cell Leukemia (EFO_0007359), Myelodysplastic Syndrome (EFO_0000198), Endocrine System Disease (EFO_0001379), Deafness (EFO_0001063), Bacterial Pneumonia (EFO_1001272), Juvenile Idiopathic Arthritis (EFO_0002609), Bursitis (MONDO_0002471), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Psoriatic Arthritis (EFO_0003778), Vestibular Neuronitis (EFO_0007537), Acute Myeloid Leukemia (EFO_0000222), Acne (EFO_0003894), Acute Graft Vs. Host Disease (EFO_0004599), Epilepsy (EFO_0000474), Immune System Disease (EFO_0000540), Secondary Progressive Multiple Sclerosis (EFO_0008522), Asthma (MONDO_0004979), Chronic Progressive Multiple Sclerosis (EFO_0003840), Anemia (MONDO_0002280), Inflammation (MP_0001845), Rheumatoid Arthritis (EFO_0000685), Osteoarthritis (MONDO_0005178), Leukemia (EFO_0000565), Type Iii Hypersensitivity Reaction Disease (EFO_1001222), Japanese Encephalitis (EFO_0007332), Posterior Uveitis (EFO_1001119), Severe Acute Respiratory Syndrome (EFO_0000694), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1417 | Q17 | What gene does the drug Bectumomab target? | The drug Bectumomab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD22. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bectumomab%" OR LOWER(tradeNames_string) LIKE "%bectumomab%" OR LOWER(drugSynonyms_string) LIKE "%bectumomab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5503', 'drugName': 'Bectumomab', 'tradeNames_string': 'Lympho scan, Lymphoscan', 'drugSynonyms_string': 'Bectumomab, IMMU-LL2, Technetium tc 99m bectumomab', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD22 (ENSG00000012124)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1567 | Q17 | What gene does the drug Volasertib target? | The drug Volasertib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PLK1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%volasertib%" OR LOWER(tradeNames_string) LIKE "%volasertib%" OR LOWER(drugSynonyms_string) LIKE "%volasertib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2040', 'drugName': 'Volasertib', 'tradeNames_string': '', 'drugSynonyms_string': 'BI 6727, BI-6727, Bi-6727, Volasertib', 'linkedDiseasesDrug_string': 'Acute Erythroblastic Leukemia (EFO_1001257), Mature T-Cell And Nk-Cell Non-Hodgkin Lymphoma (MONDO_0000430), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Non-Small Cell Lung Carcinoma (EFO_0003060), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Myelodysplastic Syndrome (EFO_0000198), Cutaneous T-Cell Lymphoma (EFO_0002913), Acute Monocytic Leukemia (EFO_0000221), Ovarian Neoplasm (EFO_0003893)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'PLK1 (ENSG00000166851)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1311 | Q17 | What gene does the drug Atracurium Besylate target? | The drug Atracurium Besylate targets 5 genes: CHRNB1, CHRNA1, CHRND, CHRNE and CHRNG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%atracurium besylate%" OR LOWER(tradeNames_string) LIKE "%atracurium besylate%" OR LOWER(drugSynonyms_string) LIKE "%atracurium besylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4801', 'drugName': 'Atracurium Besylate', 'tradeNames_string': 'Atracurium Besilate, Atracurium besylate, Atracurium besylate preservative free, Tracrium, Tracrium preservative free', 'drugSynonyms_string': 'Atracurium besilate, Atracurium besylate, Atracurium dibesylate, BW 33A, BW-33A, NSC-760047', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1983, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_3676', 'drugName': 'Cisatracurium Besylate', 'tradeNames_string': 'Cisatracurium besylate, Cisatracurium besylate preservative free, Nimbex, Nimbex preservative free', 'drugSynonyms_string': '51 W89, 51-W-89, 51-W89, 51W-89, 51W89, Cisatracurium (as besilate), Cisatracurium besilate, Cisatracurium besylate', 'linkedDiseasesDrug_string': 'Acute Respiratory Distress Syndrome (EFO_1000637)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.862 | Q17 | What gene does the drug Perindopril Arginine target? | The drug Perindopril Arginine targets the gene ACE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%perindopril arginine%" OR LOWER(tradeNames_string) LIKE "%perindopril arginine%" OR LOWER(drugSynonyms_string) LIKE "%perindopril arginine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2053', 'drugName': 'Perindopril Arginine', 'tradeNames_string': '', 'drugSynonyms_string': 'Perindopril arginine', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537), Coronary Artery Disease (EFO_0001645), Abdominal Aortic Aneurysm (EFO_0004214), Myocardial Infarction (EFO_0000612)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.591 | Q17 | What gene does the drug Iptacopan target? | The drug Iptacopan is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CFB. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%iptacopan%" OR LOWER(tradeNames_string) LIKE "%iptacopan%" OR LOWER(drugSynonyms_string) LIKE "%iptacopan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3164', 'drugName': 'Iptacopan', 'tradeNames_string': '', 'drugSynonyms_string': 'Iptacopan, LNP-023, LNP023, Lnp023, NVP-LNP023, NVP-LNP023-NX', 'linkedDiseasesDrug_string': 'Liver Disease (EFO_0001421), Atypical Hemolytic-Uremic Syndrome (MONDO_0016244), Glomerulonephritis (MONDO_0002462), Iga Glomerulonephritis (EFO_0004194), Lupus Nephritis (EFO_0005761), Age-Related Macular Degeneration (EFO_0001365), Membranous Glomerulonephritis (EFO_0004254)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CFB (ENSG00000243649)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.485 | Q17 | What gene does the drug Tafamidis Meglumine target? | The drug Tafamidis Meglumine targets the gene TTR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tafamidis meglumine%" OR LOWER(tradeNames_string) LIKE "%tafamidis meglumine%" OR LOWER(drugSynonyms_string) LIKE "%tafamidis meglumine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_8', 'drugName': 'Tafamidis Meglumine', 'tradeNames_string': 'Vyndaqel', 'drugSynonyms_string': 'FX-1006A, Tafamidis meglumine', 'linkedDiseasesDrug_string': 'Amyloidosis (EFO_1001875), Al Amyloidosis (MONDO_0019438), Polyneuropathy (EFO_0009562), Familial Amyloid Neuropathy (EFO_0004129), Cardiomyopathy (EFO_0000318)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TTR (ENSG00000118271)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1473 | Q17 | What gene does the drug Bms-275183 target? | The drug Bms-275183 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 15 genes: TUBB, TUBA4A, TUBA3E, TUBB3, TUBB4B, TUBB2A, TUBA1A, TUBA1C, TUBB1, TUBB2B, TUBB8, TUBB6, TUBB4A, TUBA3C and TUBA1B | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bms-275183%" OR LOWER(tradeNames_string) LIKE "%bms-275183%" OR LOWER(drugSynonyms_string) LIKE "%bms-275183%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5627', 'drugName': 'Bms-275183', 'tradeNames_string': '', 'drugSynonyms_string': 'Bms 275183, Bms-275183', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 15}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1784 | Q17 | What gene does the drug Marstacimab target? | The drug Marstacimab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TFPI. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%marstacimab%" OR LOWER(tradeNames_string) LIKE "%marstacimab%" OR LOWER(drugSynonyms_string) LIKE "%marstacimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6201', 'drugName': 'Marstacimab', 'tradeNames_string': '', 'drugSynonyms_string': 'Marstacimab, PF-06741086', 'linkedDiseasesDrug_string': 'Hemophilia (MONDO_0018660), Hemophilia B (MONDO_0010604), Hemophilia A (MONDO_0010602)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TFPI (ENSG00000003436)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.644 | Q17 | What gene does the drug Sb-773812 target? | The drug Sb-773812 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: HTR2A and DRD2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sb-773812%" OR LOWER(tradeNames_string) LIKE "%sb-773812%" OR LOWER(drugSynonyms_string) LIKE "%sb-773812%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_56', 'drugName': 'Sb-773812', 'tradeNames_string': '', 'drugSynonyms_string': 'GW773812, SB-737050-A, SB-773812, Sb-773812', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_57', 'drugName': 'Sb-773812', 'tradeNames_string': '', 'drugSynonyms_string': 'GW773812, SB-737050-A, SB-773812, Sb-773812', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.357 | Q17 | What gene does the drug Az9773 target? | The drug Az9773 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TNF. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%az9773%" OR LOWER(tradeNames_string) LIKE "%az9773%" OR LOWER(drugSynonyms_string) LIKE "%az9773%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3954', 'drugName': 'Az9773', 'tradeNames_string': '', 'drugSynonyms_string': 'AZ-9773, AZ9773', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'TNF (ENSG00000232810)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1128 | Q17 | What gene does the drug Benzhydrocodone target? | The drug Benzhydrocodone targets 3 genes: OPRK1, OPRM1 and OPRD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%benzhydrocodone%" OR LOWER(tradeNames_string) LIKE "%benzhydrocodone%" OR LOWER(drugSynonyms_string) LIKE "%benzhydrocodone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_529', 'drugName': 'Benzhydrocodone', 'tradeNames_string': '', 'drugSynonyms_string': 'Benzhydrocodone', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Drug Dependence (EFO_0003890)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3008', 'drugName': 'Benzhydrocodone Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Benzhydrocodone hydrochloride, KP-201, KP201', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Drug Dependence (EFO_0003890)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.439 | Q17 | What gene does the drug Pimavanserin target? | The drug Pimavanserin targets the gene HTR2A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pimavanserin%" OR LOWER(tradeNames_string) LIKE "%pimavanserin%" OR LOWER(drugSynonyms_string) LIKE "%pimavanserin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5097', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_string': 'Nuplazid', 'drugSynonyms_string': 'ACP-103, Pimavanserin tartrate', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Alzheimer Disease (MONDO_0004975), Parkinson Disease (MONDO_0005180), Hallucinations (HP_0000738), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2016, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_501', 'drugName': 'Pimavanserin', 'tradeNames_string': '', 'drugSynonyms_string': 'Pimavanserin', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Alzheimer Disease (MONDO_0004975), Tourette Syndrome (EFO_0004895), Parkinson Disease (MONDO_0005180), Neurodegenerative Disease (EFO_0005772), Major Depressive Disorder (MONDO_0002009), Hallucinations (HP_0000738), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2016, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1121 | Q17 | What gene does the drug Codeine Sulfate target? | The drug Codeine Sulfate targets 3 genes: OPRK1, OPRM1 and OPRD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%codeine sulfate%" OR LOWER(tradeNames_string) LIKE "%codeine sulfate%" OR LOWER(drugSynonyms_string) LIKE "%codeine sulfate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3666', 'drugName': 'Codeine Sulfate', 'tradeNames_string': 'Codeine sulfate', 'drugSynonyms_string': 'Codeine sulfate, Codeine sulfate anhydrous, Codeine sulfate cii, Codeine sulfate trihydrate, Codeine sulphate', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1103 | Q17 | What gene does the drug Sunitinib Malate target? | The drug Sunitinib Malate targets 9 genes: FLT4, FLT3, RET, KIT, FLT1, KDR, CSF1R, PDGFRB and PDGFRA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sunitinib malate%" OR LOWER(tradeNames_string) LIKE "%sunitinib malate%" OR LOWER(drugSynonyms_string) LIKE "%sunitinib malate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3923', 'drugName': 'Sunitinib Malate', 'tradeNames_string': 'Sunitinib malate, Sutent', 'drugSynonyms_string': 'PHA-290940AD, SU-010398, SU-011248 L-MALATE SALT, SU010398, SU011248 L-MALATE SALT, Sunitinib l-malate, Sunitinib malate, Sutent', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Islet Cell Tumor (EFO_0007331), Chronic Lymphocytic Leukemia (EFO_0000095), Mixed Glioma (MONDO_0003268), Thymic Carcinoma (EFO_1000576), Oligodendroglioma (EFO_0000632), Gastrointestinal Stromal Tumor (MONDO_0011719), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Endocrine Carcinoma (EFO_0007416), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Inflammatory Breast Carcinoma (EFO_1000984), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Kidney Neoplasm (EFO_0003865), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Germ Cell Tumor (EFO_0000514)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_3919', 'drugName': 'Sunitinib Malate', 'tradeNames_string': 'Sunitinib malate, Sutent', 'drugSynonyms_string': 'PHA-290940AD, SU-010398, SU-011248 L-MALATE SALT, SU010398, SU011248 L-MALATE SALT, Sunitinib l-malate, Sunitinib malate, Sutent', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Islet Cell Tumor (EFO_0007331), Chronic Lymphocytic Leukemia (EFO_0000095), Mixed Glioma (MONDO_0003268), Thymic Carcinoma (EFO_1000576), Oligodendroglioma (EFO_0000632), Gastrointestinal Stromal Tumor (MONDO_0011719), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Endocrine Carcinoma (EFO_0007416), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Inflammatory Breast Carcinoma (EFO_1000984), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Kidney Neoplasm (EFO_0003865), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Germ Cell Tumor (EFO_0000514)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_3918', 'drugName': 'Sunitinib Malate', 'tradeNames_string': 'Sunitinib malate, Sutent', 'drugSynonyms_string': 'PHA-290940AD, SU-010398, SU-011248 L-MALATE SALT, SU010398, SU011248 L-MALATE SALT, Sunitinib l-malate, Sunitinib malate, Sutent', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Islet Cell Tumor (EFO_0007331), Chronic Lymphocytic Leukemia (EFO_0000095), Mixed Glioma (MONDO_0003268), Thymic Carcinoma (EFO_1000576), Oligodendroglioma (EFO_0000632), Gastrointestinal Stromal Tumor (MONDO_0011719), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Endocrine Carcinoma (EFO_0007416), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Inflammatory Breast Carcinoma (EFO_1000984), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Kidney Neoplasm (EFO_0003865), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Germ Cell Tumor (EFO_0000514)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_3921', 'drugName': 'Sunitinib Malate', 'tradeNames_string': 'Sunitinib malate, Sutent', 'drugSynonyms_string': 'PHA-290940AD, SU-010398, SU-011248 L-MALATE SALT, SU010398, SU011248 L-MALATE SALT, Sunitinib l-malate, Sunitinib malate, Sutent', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Islet Cell Tumor (EFO_0007331), Chronic Lymphocytic Leukemia (EFO_0000095), Mixed Glioma (MONDO_0003268), Thymic Carcinoma (EFO_1000576), Oligodendroglioma (EFO_0000632), Gastrointestinal Stromal Tumor (MONDO_0011719), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Endocrine Carcinoma (EFO_0007416), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Inflammatory Breast Carcinoma (EFO_1000984), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Kidney Neoplasm (EFO_0003865), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Germ Cell Tumor (EFO_0000514)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_3922', 'drugName': 'Sunitinib Malate', 'tradeNames_string': 'Sunitinib malate, Sutent', 'drugSynonyms_string': 'PHA-290940AD, SU-010398, SU-011248 L-MALATE SALT, SU010398, SU011248 L-MALATE SALT, Sunitinib l-malate, Sunitinib malate, Sutent', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Islet Cell Tumor (EFO_0007331), Chronic Lymphocytic Leukemia (EFO_0000095), Mixed Glioma (MONDO_0003268), Thymic Carcinoma (EFO_1000576), Oligodendroglioma (EFO_0000632), Gastrointestinal Stromal Tumor (MONDO_0011719), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Endocrine Carcinoma (EFO_0007416), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Inflammatory Breast Carcinoma (EFO_1000984), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Kidney Neoplasm (EFO_0003865), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Germ Cell Tumor (EFO_0000514)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_3920', 'drugName': 'Sunitinib Malate', 'tradeNames_string': 'Sunitinib malate, Sutent', 'drugSynonyms_string': 'PHA-290940AD, SU-010398, SU-011248 L-MALATE SALT, SU010398, SU011248 L-MALATE SALT, Sunitinib l-malate, Sunitinib malate, Sutent', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Islet Cell Tumor (EFO_0007331), Chronic Lymphocytic Leukemia (EFO_0000095), Mixed Glioma (MONDO_0003268), Thymic Carcinoma (EFO_1000576), Oligodendroglioma (EFO_0000632), Gastrointestinal Stromal Tumor (MONDO_0011719), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Endocrine Carcinoma (EFO_0007416), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Inflammatory Breast Carcinoma (EFO_1000984), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Kidney Neoplasm (EFO_0003865), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Germ Cell Tumor (EFO_0000514)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'numberLinkedTargets': 9}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1348 | Q17 | What gene does the drug Fostamatinib target? | The drug Fostamatinib targets the gene SYK. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fostamatinib%" OR LOWER(tradeNames_string) LIKE "%fostamatinib%" OR LOWER(drugSynonyms_string) LIKE "%fostamatinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1146', 'drugName': 'Fostamatinib', 'tradeNames_string': '', 'drugSynonyms_string': 'Fostamatinib, R-788, R-788 FREE ACID, R-935788, R-935788 FREE ACID, R788 FREE ACID, R935788 FREE ACID', 'linkedDiseasesDrug_string': 'Thrombocytopenia (HP_0001873), Pneumonia (EFO_0003106), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Hemorrhage (MP_0001914), Myelofibrosis (MONDO_0044903), Covid-19 (MONDO_0100096), Anemia, Hemolytic, Autoimmune (EFO_1001264), Lymphoma (EFO_0000574), Iga Glomerulonephritis (EFO_0004194), Systemic Lupus Erythematosus (MONDO_0007915), Rheumatoid Arthritis (EFO_0000685), Diffuse Large B-Cell Lymphoma (EFO_0000403), Hidradenitis Suppurativa (EFO_1000710), Ovarian Cancer (MONDO_0008170), Lymphoid Neoplasm (EFO_0001642)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SYK (ENSG00000165025)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4030', 'drugName': 'Fostamatinib Disodium', 'tradeNames_string': 'Tavalisse', 'drugSynonyms_string': 'Fostamatinib disodium, Fostamatinib disodium hexahydrate, Fostamatinib disodium salt hexahydrate, Fostamatinib sodium hydrate, R-788 SODIUM, R-788 SODIUM HYDRATE, R-935788 SODIUM, R-935788 SODIUM HYDRATE, R788 SODIUM, R788 SODIUM HYDRATE, R935788 SODIUM, R935788 SODIUM HYDRATE', 'linkedDiseasesDrug_string': 'Thrombocytopenia (HP_0001873), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Anemia, Hemolytic, Autoimmune (EFO_1001264), Lymphoma (EFO_0000574), Iga Glomerulonephritis (EFO_0004194), Systemic Lupus Erythematosus (MONDO_0007915), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SYK (ENSG00000165025)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.597 | Q17 | What gene does the drug Vobarilizumab target? | The drug Vobarilizumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene IL6R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vobarilizumab%" OR LOWER(tradeNames_string) LIKE "%vobarilizumab%" OR LOWER(drugSynonyms_string) LIKE "%vobarilizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3070', 'drugName': 'Vobarilizumab', 'tradeNames_string': '', 'drugSynonyms_string': 'ALX-0061, ALX0061, Vobarilizumab', 'linkedDiseasesDrug_string': 'Systemic Lupus Erythematosus (MONDO_0007915), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'IL6R (ENSG00000160712)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1368 | Q17 | What gene does the drug Oxprenolol target? | The drug Oxprenolol targets 2 genes: ADRB2 and ADRB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxprenolol%" OR LOWER(tradeNames_string) LIKE "%oxprenolol%" OR LOWER(drugSynonyms_string) LIKE "%oxprenolol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3598', 'drugName': 'Oxprenolol', 'tradeNames_string': '', 'drugSynonyms_string': 'Oxprenolol', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1983, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3597', 'drugName': 'Oxprenolol', 'tradeNames_string': '', 'drugSynonyms_string': 'Oxprenolol', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1983, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_153', 'drugName': 'Oxprenolol Hydrochloride', 'tradeNames_string': 'Apsolox, Laracor, Oxyprenix excel 160, Paritane, Slow-pren, Slow-trasicor, Trasicor, Trasicor ret', 'drugSynonyms_string': 'BA-39,089, BA-39089, Oxprenolol hcl, Oxprenolol hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1983, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_152', 'drugName': 'Oxprenolol Hydrochloride', 'tradeNames_string': 'Apsolox, Laracor, Oxyprenix excel 160, Paritane, Slow-pren, Slow-trasicor, Trasicor, Trasicor ret', 'drugSynonyms_string': 'BA-39,089, BA-39089, Oxprenolol hcl, Oxprenolol hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1983, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1401 | Q17 | What gene does the drug Palbociclib target? | The drug Palbociclib targets 3 genes: CDK6, CDK4 and CCND1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%palbociclib%" OR LOWER(tradeNames_string) LIKE "%palbociclib%" OR LOWER(drugSynonyms_string) LIKE "%palbociclib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2460', 'drugName': 'Palbociclib', 'tradeNames_string': 'Ibrance', 'drugSynonyms_string': 'PD-0332991, Palbociclib', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Pancreatic Neuroendocrine Tumor (EFO_1000045), Non-Hodgkins Lymphoma (EFO_0005952), Covid-19 (MONDO_0100096), Oligodendroglioma (EFO_0000632), Urothelial Carcinoma (EFO_0008528), Breast Ductal Adenocarcinoma (EFO_0006318), Colon Carcinoma (EFO_1001950), Squamous Cell Lung Carcinoma (EFO_0000708), Endometrial Cancer (MONDO_0011962), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Mantle Cell Lymphoma (EFO_1001469), Oligoastrocytoma (EFO_0000630), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Liposarcoma (EFO_0000569), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pancreatic Carcinoma (EFO_0002618), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thymus Neoplasm (EFO_0002626), Head And Neck Malignant Neoplasia (EFO_0006859), Osteosarcoma (EFO_0000637), Ewing Sarcoma (EFO_0000174), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Lung Cancer (MONDO_0008903), Adenocarcinoma (EFO_0000228), Chordoma (MONDO_0008978), Non-Small Cell Lung Carcinoma (EFO_0003060), Nasopharyngeal Neoplasm (EFO_0004252), Kidney Disease (EFO_0003086), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CCND1 (ENSG00000110092), CDK6 (ENSG00000105810), CDK4 (ENSG00000135446)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2461', 'drugName': 'Palbociclib', 'tradeNames_string': 'Ibrance', 'drugSynonyms_string': 'PD-0332991, Palbociclib', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Pancreatic Neuroendocrine Tumor (EFO_1000045), Non-Hodgkins Lymphoma (EFO_0005952), Covid-19 (MONDO_0100096), Oligodendroglioma (EFO_0000632), Urothelial Carcinoma (EFO_0008528), Breast Ductal Adenocarcinoma (EFO_0006318), Colon Carcinoma (EFO_1001950), Squamous Cell Lung Carcinoma (EFO_0000708), Endometrial Cancer (MONDO_0011962), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Mantle Cell Lymphoma (EFO_1001469), Oligoastrocytoma (EFO_0000630), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Liposarcoma (EFO_0000569), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pancreatic Carcinoma (EFO_0002618), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thymus Neoplasm (EFO_0002626), Head And Neck Malignant Neoplasia (EFO_0006859), Osteosarcoma (EFO_0000637), Ewing Sarcoma (EFO_0000174), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Lung Cancer (MONDO_0008903), Adenocarcinoma (EFO_0000228), Chordoma (MONDO_0008978), Non-Small Cell Lung Carcinoma (EFO_0003060), Nasopharyngeal Neoplasm (EFO_0004252), Kidney Disease (EFO_0003086), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CCND1 (ENSG00000110092), CDK6 (ENSG00000105810), CDK4 (ENSG00000135446)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.753 | Q17 | What gene does the drug Neramexane target? | The drug Neramexane is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 9 genes: GRIN2B, GRIN2A, GRIN3A, GRIN2D, CHRNA9, GRIN3B, GRIN1, CHRNA10 and GRIN2C | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%neramexane%" OR LOWER(tradeNames_string) LIKE "%neramexane%" OR LOWER(drugSynonyms_string) LIKE "%neramexane%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3405', 'drugName': 'Neramexane', 'tradeNames_string': '', 'drugSynonyms_string': 'Neramexane', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Tinnitus (HP_0000360)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), CHRNA9 (ENSG00000174343), CHRNA10 (ENSG00000129749)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_3404', 'drugName': 'Neramexane', 'tradeNames_string': '', 'drugSynonyms_string': 'Neramexane', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Tinnitus (HP_0000360)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), CHRNA9 (ENSG00000174343), CHRNA10 (ENSG00000129749)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_5794', 'drugName': 'Neramexane Mesylate', 'tradeNames_string': '', 'drugSynonyms_string': 'Neramexane mesilate, Neramexane mesylate', 'linkedDiseasesDrug_string': 'Tinnitus (HP_0000360)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA9 (ENSG00000174343), CHRNA10 (ENSG00000129749), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_5793', 'drugName': 'Neramexane Mesylate', 'tradeNames_string': '', 'drugSynonyms_string': 'Neramexane mesilate, Neramexane mesylate', 'linkedDiseasesDrug_string': 'Tinnitus (HP_0000360)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA9 (ENSG00000174343), CHRNA10 (ENSG00000129749), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'numberLinkedTargets': 9}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.259 | Q17 | What gene does the drug Ezutromid target? | The drug Ezutromid is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene UTRN. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ezutromid%" OR LOWER(tradeNames_string) LIKE "%ezutromid%" OR LOWER(drugSynonyms_string) LIKE "%ezutromid%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2700', 'drugName': 'Ezutromid', 'tradeNames_string': '', 'drugSynonyms_string': 'BMN 195, BMN-195, Ezutromid, SMT-C1100, SMTC-1100, Smt c1100', 'linkedDiseasesDrug_string': 'Duchenne Muscular Dystrophy (MONDO_0010679)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'UTRN (ENSG00000152818)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1687 | Q17 | What gene does the drug Txa127 target? | The drug Txa127 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MAS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%txa127%" OR LOWER(tradeNames_string) LIKE "%txa127%" OR LOWER(drugSynonyms_string) LIKE "%txa127%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2902', 'drugName': 'Txa127', 'tradeNames_string': '', 'drugSynonyms_string': '5-ile-angiotensin-(1-7), Angiotensin (1-7), Angiotensin 1-7, Angiotensin fragment 1-7, Angiotensin peptide (1-7), Angiotensin-(1-7), Asp-arg-val-tyr-ile-his-pro, Bf-angiotensin 1-7, Human angiotensin ii (1-7), Sh-heptapeptide-13, TXA-127, TXA127, Txa127', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Hiv Infection (EFO_0000764), Neoplasm (EFO_0000616), Peripheral Arterial Disease (EFO_0004265), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Aging (GO_0007568), Obesity (EFO_0001073), Covid-19 (MONDO_0100096), Respiratory Failure (EFO_0009686), Myelodysplastic Syndrome (EFO_0000198)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAS1 (ENSG00000130368)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1723 | Q17 | What gene does the drug Nktr-171 target? | The drug Nktr-171 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nktr-171%" OR LOWER(tradeNames_string) LIKE "%nktr-171%" OR LOWER(drugSynonyms_string) LIKE "%nktr-171%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_124', 'drugName': 'Nktr-171', 'tradeNames_string': '', 'drugSynonyms_string': 'Nktr-171', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.544 | Q17 | What gene does the drug Clenbuterol target? | The drug Clenbuterol targets the gene ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clenbuterol%" OR LOWER(tradeNames_string) LIKE "%clenbuterol%" OR LOWER(drugSynonyms_string) LIKE "%clenbuterol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1386', 'drugName': 'Clenbuterol', 'tradeNames_string': 'Spiropent, Spiropent mite', 'drugSynonyms_string': 'Clenbuterol, Clenbuterol hydrochloride, Contraspasmin, NAB 365, NSC-758633, Planipart', 'linkedDiseasesDrug_string': 'Amyotrophic Lateral Sclerosis (MONDO_0004976), Parkinson Disease (MONDO_0005180), Airway Obstruction (HP_0006536), Glycogen Storage Disease Due To Acid Maltase Deficiency (Orphanet_365), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.792 | Q17 | What gene does the drug Asoprisnil target? | The drug Asoprisnil is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PGR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%asoprisnil%" OR LOWER(tradeNames_string) LIKE "%asoprisnil%" OR LOWER(drugSynonyms_string) LIKE "%asoprisnil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4647', 'drugName': 'Asoprisnil', 'tradeNames_string': '', 'drugSynonyms_string': 'Asoprisnil, BAY86-5294, J-867, J867', 'linkedDiseasesDrug_string': 'Menorrhagia (HP_0000132), Leiomyoma (MONDO_0001572), Menopause (EFO_0003922), Uterine Fibroid (EFO_0000731), Metrorrhagia (HP_0100608), Endometriosis (EFO_0001065)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1484 | Q17 | What gene does the drug Follitropin Alfa target? | The drug Follitropin Alfa targets the gene FSHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%follitropin alfa%" OR LOWER(tradeNames_string) LIKE "%follitropin alfa%" OR LOWER(drugSynonyms_string) LIKE "%follitropin alfa%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2306', 'drugName': 'Corifollitropin Alfa', 'tradeNames_string': 'Elonva', 'drugSynonyms_string': 'Corifollitropin alfa, MK-8962, ORG 36286, ORG-36286, SCH 900962, SCH-900962', 'linkedDiseasesDrug_string': 'Infertility (EFO_0000545), Hypogonadotropic Hypogonadism (MONDO_0018555)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FSHR (ENSG00000170820)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_206', 'drugName': 'Follitropin Alfa', 'tradeNames_string': 'Bemfola, Follistim, Follistim aq, Gonal-f, Gonal-f rff, Gonal-f rff redi-ject, Ovaleap, Puregon', 'drugSynonyms_string': 'Follitropin alfa, Follitropin alfa/beta, Follitropin beta, Fsh (menotropins), Human FSH', 'linkedDiseasesDrug_string': 'Polycystic Ovary Syndrome (EFO_0000660), Female Infertility (EFO_0008560), Anovulation (MONDO_0002775), Infertility (EFO_0000545)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FSHR (ENSG00000170820)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.420 | Q17 | What gene does the drug Darapladib target? | The drug Darapladib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PLA2G7. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%darapladib%" OR LOWER(tradeNames_string) LIKE "%darapladib%" OR LOWER(drugSynonyms_string) LIKE "%darapladib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5024', 'drugName': 'Darapladib', 'tradeNames_string': '', 'drugSynonyms_string': 'Darapladib, SB-480848', 'linkedDiseasesDrug_string': 'Acute Coronary Syndrome (EFO_0005672), Diabetic Retinopathy (EFO_0003770), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'PLA2G7 (ENSG00000146070)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1849 | Q17 | What gene does the drug Ethacrynate Sodium target? | The drug Ethacrynate Sodium targets the gene SLC12A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ethacrynate sodium%" OR LOWER(tradeNames_string) LIKE "%ethacrynate sodium%" OR LOWER(drugSynonyms_string) LIKE "%ethacrynate sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3044', 'drugName': 'Ethacrynate Sodium', 'tradeNames_string': 'Edecrin, Ethacrynate sodium', 'drugSynonyms_string': 'Etacrynate sodium, Ethacrynate sodium, Ethacrynic acid sodium salt, Sodium etacrynate, Sodium ethacrynate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC12A1 (ENSG00000074803)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1920 | Q17 | What gene does the drug Exenatide target? | The drug Exenatide targets the gene GLP1R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%exenatide%" OR LOWER(tradeNames_string) LIKE "%exenatide%" OR LOWER(drugSynonyms_string) LIKE "%exenatide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3783', 'drugName': 'Exenatide', 'tradeNames_string': 'Bydureon, Bydureon bcise, Bydureon pen, Byetta', 'drugSynonyms_string': 'AC 2993, AC-002993, AC-2993, AC-2993A, AC-2993LAR, AC002993, AC2993, AC2993A, DA-3091, EXENDIN-4, Exenatide, Exenatide Synthetic, Exenatide synthetic, Exendin 4, ITCA-650, LY-2148568, LY2148568', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Coronary Artery Disease (EFO_0001645), Obesity (EFO_0001073), Hyperinsulinemic Hypoglycemia (EFO_0007318), Polycystic Ovary Syndrome (EFO_0000660), Hyperglycemia (HP_0003074), Ischemic Stroke (HP_0002140), Parkinson Disease (MONDO_0005180), Acute Myocardial Infarction (EFO_0008583), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Multiple System Atrophy (EFO_1001050), Cocaine Dependence (EFO_0002610), Renal Insufficiency (HP_0000083), Morbid Obesity (EFO_0001074), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Cerebral Small Vessel Disease (EFO_0008493), Alcohol Dependence (MONDO_0007079), Smoking Cessation (EFO_0004319), Weight Loss (HP_0001824), Prediabetes Syndrome (EFO_1001121), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GLP1R (ENSG00000112164)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1099 | Q17 | What gene does the drug Aripiprazole target? | The drug Aripiprazole targets 3 genes: HTR2A, HTR1A and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aripiprazole%" OR LOWER(tradeNames_string) LIKE "%aripiprazole%" OR LOWER(drugSynonyms_string) LIKE "%aripiprazole%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4681', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_string': 'Aristada, Aristada initio kit', 'drugSynonyms_string': 'ALKS 9072, ALKS-9070, ALKS-9072, Aripiprazole lauroxil, Aristada initio, RDC-3317, RDC3317', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Bipolar I Disorder (EFO_0009963), Tourette Syndrome (EFO_0004895), Schizoaffective Disorder (EFO_0005411), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468), HTR1A (ENSG00000178394)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2620', 'drugName': 'Aripiprazole', 'tradeNames_string': 'Abilify, Abilify maintena, Abilify maintena kit, Abilify mycite kit, Aripiprazole', 'drugSynonyms_string': 'Abilify mycite, Aripiprazole, Aripiprex, NSC-759266, OPC-14597, OPC-31', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Alzheimer Disease (MONDO_0004975), Bipolar I Disorder (EFO_0009963), Agitation (HP_0000713), Tourette Syndrome (EFO_0004895), Anorexia Nervosa (MONDO_0005351), Post-Traumatic Stress Disorder (EFO_0001358), Postpartum Depression (EFO_0007453), Fragile X Syndrome (MONDO_0010383), Dementia (HP_0000726), Schizoaffective Disorder (EFO_0005411), Anxiety (EFO_0005230), Attention Deficit Hyperactivity Disorder (EFO_0003888), Cocaine Dependence (EFO_0002610), Autism Spectrum Disorder (EFO_0003756), Aggressive Behavior (EFO_0003015), Methamphetamine Dependence (EFO_0004701), Obsessive-Compulsive Disorder (EFO_0004242), Pervasive Developmental Disorder (MONDO_0000594), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Psychosis (EFO_0005407), Unipolar Depression (EFO_0003761), Asperger Syndrome (EFO_0003757), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1A (ENSG00000178394), DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2619', 'drugName': 'Aripiprazole', 'tradeNames_string': 'Abilify, Abilify maintena, Abilify maintena kit, Abilify mycite kit, Aripiprazole', 'drugSynonyms_string': 'Abilify mycite, Aripiprazole, Aripiprex, NSC-759266, OPC-14597, OPC-31', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Alzheimer Disease (MONDO_0004975), Bipolar I Disorder (EFO_0009963), Agitation (HP_0000713), Tourette Syndrome (EFO_0004895), Anorexia Nervosa (MONDO_0005351), Post-Traumatic Stress Disorder (EFO_0001358), Postpartum Depression (EFO_0007453), Fragile X Syndrome (MONDO_0010383), Dementia (HP_0000726), Schizoaffective Disorder (EFO_0005411), Anxiety (EFO_0005230), Attention Deficit Hyperactivity Disorder (EFO_0003888), Cocaine Dependence (EFO_0002610), Autism Spectrum Disorder (EFO_0003756), Aggressive Behavior (EFO_0003015), Methamphetamine Dependence (EFO_0004701), Obsessive-Compulsive Disorder (EFO_0004242), Pervasive Developmental Disorder (MONDO_0000594), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Psychosis (EFO_0005407), Unipolar Depression (EFO_0003761), Asperger Syndrome (EFO_0003757), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1A (ENSG00000178394), DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4679', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_string': 'Aristada, Aristada initio kit', 'drugSynonyms_string': 'ALKS 9072, ALKS-9070, ALKS-9072, Aripiprazole lauroxil, Aristada initio, RDC-3317, RDC3317', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Bipolar I Disorder (EFO_0009963), Tourette Syndrome (EFO_0004895), Schizoaffective Disorder (EFO_0005411), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468), HTR1A (ENSG00000178394)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4680', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_string': 'Aristada, Aristada initio kit', 'drugSynonyms_string': 'ALKS 9072, ALKS-9070, ALKS-9072, Aripiprazole lauroxil, Aristada initio, RDC-3317, RDC3317', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Bipolar I Disorder (EFO_0009963), Tourette Syndrome (EFO_0004895), Schizoaffective Disorder (EFO_0005411), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468), HTR1A (ENSG00000178394)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2621', 'drugName': 'Aripiprazole', 'tradeNames_string': 'Abilify, Abilify maintena, Abilify maintena kit, Abilify mycite kit, Aripiprazole', 'drugSynonyms_string': 'Abilify mycite, Aripiprazole, Aripiprex, NSC-759266, OPC-14597, OPC-31', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Alzheimer Disease (MONDO_0004975), Bipolar I Disorder (EFO_0009963), Agitation (HP_0000713), Tourette Syndrome (EFO_0004895), Anorexia Nervosa (MONDO_0005351), Post-Traumatic Stress Disorder (EFO_0001358), Postpartum Depression (EFO_0007453), Fragile X Syndrome (MONDO_0010383), Dementia (HP_0000726), Schizoaffective Disorder (EFO_0005411), Anxiety (EFO_0005230), Attention Deficit Hyperactivity Disorder (EFO_0003888), Cocaine Dependence (EFO_0002610), Autism Spectrum Disorder (EFO_0003756), Aggressive Behavior (EFO_0003015), Methamphetamine Dependence (EFO_0004701), Obsessive-Compulsive Disorder (EFO_0004242), Pervasive Developmental Disorder (MONDO_0000594), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Psychosis (EFO_0005407), Unipolar Depression (EFO_0003761), Asperger Syndrome (EFO_0003757), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1A (ENSG00000178394), DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.845 | Q17 | What gene does the drug Olopatadine Hydrochloride target? | The drug Olopatadine Hydrochloride targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%olopatadine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%olopatadine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%olopatadine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6184', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_string': 'Olopatadine hydrochloride, Pataday, Pataday once daily relief, Pataday twice daily relief, Patanase, Patanol, Pazeo', 'drugSynonyms_string': 'ALO-4943A, ALO4943A, Allelock, KW-4679, KW4679, Olopatadine (as hydrochloride), Olopatadine hcl, Olopatadine hydrochloride', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Seasonal Allergic Rhinitis (EFO_0003956), Pruritus (HP_0000989), Allergic Rhinitis (EFO_0005854)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.68 | Q17 | What gene does the drug Icenticaftor target? | The drug Icenticaftor is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CFTR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%icenticaftor%" OR LOWER(tradeNames_string) LIKE "%icenticaftor%" OR LOWER(drugSynonyms_string) LIKE "%icenticaftor%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3554', 'drugName': 'Icenticaftor', 'tradeNames_string': '', 'drugSynonyms_string': 'Icenticaftor, Qbw251', 'linkedDiseasesDrug_string': 'Cystic Fibrosis (MONDO_0009061), Hepatic Failure (HP_0001399), Chronic Obstructive Pulmonary Disease (EFO_0000341)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CFTR (ENSG00000001626)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1698 | Q17 | What gene does the drug Cimetidine Hydrochloride target? | The drug Cimetidine Hydrochloride targets the gene HRH2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cimetidine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%cimetidine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%cimetidine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4862', 'drugName': 'Cimetidine Hydrochloride', 'tradeNames_string': 'Cimetidine hydrochloride, Tagamet', 'drugSynonyms_string': 'Cimetidine hcl, Cimetidine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH2 (ENSG00000113749)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1733 | Q17 | What gene does the drug Sevoflurane target? | The drug Sevoflurane targets 23 genes: GLRB, GABRG2, GABRA4, KCNK9, GABRB3, GABRA2, KCNK3, KCNK10, GABRA1, GLRA1, GABRE, GABRP, GABRG3, GABRB1, GABRA6, KCNK2, KCNK18, GABRA5, GABRQ, GABRD, GABRA3, GABRB2 and GABRG1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sevoflurane%" OR LOWER(tradeNames_string) LIKE "%sevoflurane%" OR LOWER(drugSynonyms_string) LIKE "%sevoflurane%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2923', 'drugName': 'Sevoflurane', 'tradeNames_string': 'Sevoflurane, Sojourn, Ultane', 'drugSynonyms_string': 'MR-6S4, MR6S4, NSC-760367, Sevocalm, Sevoflo, Sevoflurane, Sevorane', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Coronary Artery Disease (EFO_0001645), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Obesity (EFO_0001073), Kidney Failure (EFO_1002048), Colorectal Carcinoma (EFO_1001951), Breast Cancer (MONDO_0007254), Septic Shock (EFO_0006834), Acute Myocardial Infarction (EFO_0008583), Acute Respiratory Distress Syndrome (EFO_1000637), Morbid Obesity (EFO_0001074), Brain Aneurysm (EFO_0003870), Delirium (EFO_0009267), Back Pain (HP_0003418), Subarachnoid Hemorrhage (EFO_0000713), Lung Neoplasm (MONDO_0021117), Inflammation (MP_0001845), Brain Injury (MONDO_0043510), Recurrent Tonsillitis (HP_0011110), Alcohol-Related Disorders (MONDO_0021698), Opioid Dependence (EFO_0005611), Congenital Heart Disease (EFO_0005207), Fluoride Poisoning (EFO_1001328), Chronic Kidney Disease (EFO_0003884), Heart Disease (EFO_0003777), Ischemia Reperfusion Injury (EFO_0002687), Post-Operative Sign Or Symptom (EFO_0005323), Respiratory Failure (EFO_0009686), Acute Kidney Injury (HP_0001919), Severe Acute Respiratory Syndrome (EFO_0000694), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_2921', 'drugName': 'Sevoflurane', 'tradeNames_string': 'Sevoflurane, Sojourn, Ultane', 'drugSynonyms_string': 'MR-6S4, MR6S4, NSC-760367, Sevocalm, Sevoflo, Sevoflurane, Sevorane', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Coronary Artery Disease (EFO_0001645), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Obesity (EFO_0001073), Kidney Failure (EFO_1002048), Colorectal Carcinoma (EFO_1001951), Breast Cancer (MONDO_0007254), Septic Shock (EFO_0006834), Acute Myocardial Infarction (EFO_0008583), Acute Respiratory Distress Syndrome (EFO_1000637), Morbid Obesity (EFO_0001074), Brain Aneurysm (EFO_0003870), Delirium (EFO_0009267), Back Pain (HP_0003418), Subarachnoid Hemorrhage (EFO_0000713), Lung Neoplasm (MONDO_0021117), Inflammation (MP_0001845), Brain Injury (MONDO_0043510), Recurrent Tonsillitis (HP_0011110), Alcohol-Related Disorders (MONDO_0021698), Opioid Dependence (EFO_0005611), Congenital Heart Disease (EFO_0005207), Fluoride Poisoning (EFO_1001328), Chronic Kidney Disease (EFO_0003884), Heart Disease (EFO_0003777), Ischemia Reperfusion Injury (EFO_0002687), Post-Operative Sign Or Symptom (EFO_0005323), Respiratory Failure (EFO_0009686), Acute Kidney Injury (HP_0001919), Severe Acute Respiratory Syndrome (EFO_0000694), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_2919', 'drugName': 'Sevoflurane', 'tradeNames_string': 'Sevoflurane, Sojourn, Ultane', 'drugSynonyms_string': 'MR-6S4, MR6S4, NSC-760367, Sevocalm, Sevoflo, Sevoflurane, Sevorane', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Coronary Artery Disease (EFO_0001645), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Obesity (EFO_0001073), Kidney Failure (EFO_1002048), Colorectal Carcinoma (EFO_1001951), Breast Cancer (MONDO_0007254), Septic Shock (EFO_0006834), Acute Myocardial Infarction (EFO_0008583), Acute Respiratory Distress Syndrome (EFO_1000637), Morbid Obesity (EFO_0001074), Brain Aneurysm (EFO_0003870), Delirium (EFO_0009267), Back Pain (HP_0003418), Subarachnoid Hemorrhage (EFO_0000713), Lung Neoplasm (MONDO_0021117), Inflammation (MP_0001845), Brain Injury (MONDO_0043510), Recurrent Tonsillitis (HP_0011110), Alcohol-Related Disorders (MONDO_0021698), Opioid Dependence (EFO_0005611), Congenital Heart Disease (EFO_0005207), Fluoride Poisoning (EFO_1001328), Chronic Kidney Disease (EFO_0003884), Heart Disease (EFO_0003777), Ischemia Reperfusion Injury (EFO_0002687), Post-Operative Sign Or Symptom (EFO_0005323), Respiratory Failure (EFO_0009686), Acute Kidney Injury (HP_0001919), Severe Acute Respiratory Syndrome (EFO_0000694), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_2918', 'drugName': 'Sevoflurane', 'tradeNames_string': 'Sevoflurane, Sojourn, Ultane', 'drugSynonyms_string': 'MR-6S4, MR6S4, NSC-760367, Sevocalm, Sevoflo, Sevoflurane, Sevorane', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Coronary Artery Disease (EFO_0001645), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Obesity (EFO_0001073), Kidney Failure (EFO_1002048), Colorectal Carcinoma (EFO_1001951), Breast Cancer (MONDO_0007254), Septic Shock (EFO_0006834), Acute Myocardial Infarction (EFO_0008583), Acute Respiratory Distress Syndrome (EFO_1000637), Morbid Obesity (EFO_0001074), Brain Aneurysm (EFO_0003870), Delirium (EFO_0009267), Back Pain (HP_0003418), Subarachnoid Hemorrhage (EFO_0000713), Lung Neoplasm (MONDO_0021117), Inflammation (MP_0001845), Brain Injury (MONDO_0043510), Recurrent Tonsillitis (HP_0011110), Alcohol-Related Disorders (MONDO_0021698), Opioid Dependence (EFO_0005611), Congenital Heart Disease (EFO_0005207), Fluoride Poisoning (EFO_1001328), Chronic Kidney Disease (EFO_0003884), Heart Disease (EFO_0003777), Ischemia Reperfusion Injury (EFO_0002687), Post-Operative Sign Or Symptom (EFO_0005323), Respiratory Failure (EFO_0009686), Acute Kidney Injury (HP_0001919), Severe Acute Respiratory Syndrome (EFO_0000694), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_2924', 'drugName': 'Sevoflurane', 'tradeNames_string': 'Sevoflurane, Sojourn, Ultane', 'drugSynonyms_string': 'MR-6S4, MR6S4, NSC-760367, Sevocalm, Sevoflo, Sevoflurane, Sevorane', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Coronary Artery Disease (EFO_0001645), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Obesity (EFO_0001073), Kidney Failure (EFO_1002048), Colorectal Carcinoma (EFO_1001951), Breast Cancer (MONDO_0007254), Septic Shock (EFO_0006834), Acute Myocardial Infarction (EFO_0008583), Acute Respiratory Distress Syndrome (EFO_1000637), Morbid Obesity (EFO_0001074), Brain Aneurysm (EFO_0003870), Delirium (EFO_0009267), Back Pain (HP_0003418), Subarachnoid Hemorrhage (EFO_0000713), Lung Neoplasm (MONDO_0021117), Inflammation (MP_0001845), Brain Injury (MONDO_0043510), Recurrent Tonsillitis (HP_0011110), Alcohol-Related Disorders (MONDO_0021698), Opioid Dependence (EFO_0005611), Congenital Heart Disease (EFO_0005207), Fluoride Poisoning (EFO_1001328), Chronic Kidney Disease (EFO_0003884), Heart Disease (EFO_0003777), Ischemia Reperfusion Injury (EFO_0002687), Post-Operative Sign Or Symptom (EFO_0005323), Respiratory Failure (EFO_0009686), Acute Kidney Injury (HP_0001919), Severe Acute Respiratory Syndrome (EFO_0000694), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_2922', 'drugName': 'Sevoflurane', 'tradeNames_string': 'Sevoflurane, Sojourn, Ultane', 'drugSynonyms_string': 'MR-6S4, MR6S4, NSC-760367, Sevocalm, Sevoflo, Sevoflurane, Sevorane', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Coronary Artery Disease (EFO_0001645), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Obesity (EFO_0001073), Kidney Failure (EFO_1002048), Colorectal Carcinoma (EFO_1001951), Breast Cancer (MONDO_0007254), Septic Shock (EFO_0006834), Acute Myocardial Infarction (EFO_0008583), Acute Respiratory Distress Syndrome (EFO_1000637), Morbid Obesity (EFO_0001074), Brain Aneurysm (EFO_0003870), Delirium (EFO_0009267), Back Pain (HP_0003418), Subarachnoid Hemorrhage (EFO_0000713), Lung Neoplasm (MONDO_0021117), Inflammation (MP_0001845), Brain Injury (MONDO_0043510), Recurrent Tonsillitis (HP_0011110), Alcohol-Related Disorders (MONDO_0021698), Opioid Dependence (EFO_0005611), Congenital Heart Disease (EFO_0005207), Fluoride Poisoning (EFO_1001328), Chronic Kidney Disease (EFO_0003884), Heart Disease (EFO_0003777), Ischemia Reperfusion Injury (EFO_0002687), Post-Operative Sign Or Symptom (EFO_0005323), Respiratory Failure (EFO_0009686), Acute Kidney Injury (HP_0001919), Severe Acute Respiratory Syndrome (EFO_0000694), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_2920', 'drugName': 'Sevoflurane', 'tradeNames_string': 'Sevoflurane, Sojourn, Ultane', 'drugSynonyms_string': 'MR-6S4, MR6S4, NSC-760367, Sevocalm, Sevoflo, Sevoflurane, Sevorane', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Coronary Artery Disease (EFO_0001645), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Obesity (EFO_0001073), Kidney Failure (EFO_1002048), Colorectal Carcinoma (EFO_1001951), Breast Cancer (MONDO_0007254), Septic Shock (EFO_0006834), Acute Myocardial Infarction (EFO_0008583), Acute Respiratory Distress Syndrome (EFO_1000637), Morbid Obesity (EFO_0001074), Brain Aneurysm (EFO_0003870), Delirium (EFO_0009267), Back Pain (HP_0003418), Subarachnoid Hemorrhage (EFO_0000713), Lung Neoplasm (MONDO_0021117), Inflammation (MP_0001845), Brain Injury (MONDO_0043510), Recurrent Tonsillitis (HP_0011110), Alcohol-Related Disorders (MONDO_0021698), Opioid Dependence (EFO_0005611), Congenital Heart Disease (EFO_0005207), Fluoride Poisoning (EFO_1001328), Chronic Kidney Disease (EFO_0003884), Heart Disease (EFO_0003777), Ischemia Reperfusion Injury (EFO_0002687), Post-Operative Sign Or Symptom (EFO_0005323), Respiratory Failure (EFO_0009686), Acute Kidney Injury (HP_0001919), Severe Acute Respiratory Syndrome (EFO_0000694), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'numberLinkedTargets': 23}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.380 | Q17 | What gene does the drug Hydromorphone Hydrochloride target? | The drug Hydromorphone Hydrochloride targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hydromorphone hydrochloride%" OR LOWER(tradeNames_string) LIKE "%hydromorphone hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%hydromorphone hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_245', 'drugName': 'Morphine', 'tradeNames_string': '', 'drugSynonyms_string': 'Anhydrous morphine, Avinza, Depodur, Hydromorphone hydrochloride impurity, morphine-, IDS-NM-009, Infumorph, Kadian, Morphia, Morphine, Morphine (anhydrous), Morphine anhydrous, Morphine extended release, Morphine polistirex, Morphium, N02AA01, Nepenthe, Ospalivina', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Rheumatic Disease (EFO_0005755), Hemorrhage (MP_0001914), Pain (EFO_0003843), Neonatal Abstinence Syndrome (EFO_0005799), Obesity (EFO_0001073), Pulmonary Arterial Hypertension (EFO_0001361), Injury (EFO_0000546), Idiopathic Pulmonary Fibrosis (EFO_0000768), Pregnancy (EFO_0002950), Nephrolithiasis (EFO_0004253), Prostate Cancer (MONDO_0008315), Rotator Cuff Tear (EFO_1001250), Osteoarthritis, Knee (EFO_0004616), Neuropathic Pain (EFO_0005762), Acute Myocardial Infarction (EFO_0008583), Acute Myeloid Leukemia (EFO_0000222), Scoliosis (EFO_0004273), Respiratory Depression (EFO_0009842), Rib Fracture (EFO_0009620), Bone Fracture (EFO_0003931), Pruritus (HP_0000989), Heroin Dependence (EFO_0004240), Restless Legs Syndrome (EFO_0004270), Cardiac Arrest (EFO_0009492), Drug Dependence (EFO_0003890), Premature Birth (EFO_0003917), Renal Colic (EFO_1001412), Sickle Cell Anemia (MONDO_0011382), Chronic Obstructive Pulmonary Disease (EFO_0000341), Back Pain (HP_0003418), Myocardial Infarction (EFO_0000612), Constipation (HP_0002019), Obstructive Sleep Apnea (EFO_0003918), Recurrent Tonsillitis (HP_0011110), Opioid Dependence (EFO_0005611), Shortness Of Breath (EFO_0009727), Head And Neck Malignant Neoplasia (EFO_0006859), Opioid Use Disorder (EFO_0010702), Neoplasm (EFO_0000616), Post-Operative Sign Or Symptom (EFO_0005323), Adenocarcinoma (EFO_0000228), Stomatitis (EFO_0009688), Chronic Pain (HP_0012532), Blood Coagulation Disease (EFO_0009314), Mucositis (EFO_1001898), Hallux Valgus (HP_0001822), Low Back Pain (HP_0003419), Multiple Bone Fractures (EFO_0009513)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4427', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_string': 'Dilaudid, Dilaudid-hp, Exalgo, Hydromorphone hydrochloride, Palladone, Palladone-sr', 'drugSynonyms_string': 'Dihydromorphinone hydrochloride, Hydromorphone HCl, Hydromorphone hcl, Hydromorphone hydrochloride, Hydromorphone hydrochloride cii, NSC-117862', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Drug Dependence (EFO_0003890), Osteoarthritis, Hip (EFO_1000786), Liver Disease (EFO_0001421), Pain (EFO_0003843), Chronic Pain (HP_0012532), Osteoarthritis, Knee (EFO_0004616), Back Pain (HP_0003418)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.240 | Q17 | What gene does the drug Stanozolol target? | The drug Stanozolol targets the gene AR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%stanozolol%" OR LOWER(tradeNames_string) LIKE "%stanozolol%" OR LOWER(drugSynonyms_string) LIKE "%stanozolol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5791', 'drugName': 'Stanozolol', 'tradeNames_string': 'Stromba, Tevabolin, Winstrol', 'drugSynonyms_string': 'Androstanazol, Androstanazole, NSC-233046, NSC-43193, Stanozolol, Stanozolol ciii, WIN 14833, WIN-14833, Winstrol, Winstrol Depot', 'linkedDiseasesDrug_string': 'Myelodysplastic Syndrome (EFO_0000198)', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.257 | Q17 | What gene does the drug Promazine Hydrochloride target? | The drug Promazine Hydrochloride targets 4 genes: DRD3, HTR2A, DRD4 and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%promazine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%promazine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%promazine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2783', 'drugName': 'Chlorpromazine Hydrochloride', 'tradeNames_string': 'Chloractil, Chlorazine, Chlorpromazine hydrochloride, Chlorpromazine hydrochloride intensol, Largactil, Largactil fte, Promapar, Rimazine, Sonazine, Thorazine', 'drugSynonyms_string': 'Chlorpromazine HCl, Chlorpromazine hcl, Chlorpromazine hydrochloride, Chlorpromazini hydrochloridum, Klorproman, Marazine, NSC-17479, Nci-c05210, Norcozine', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_4009', 'drugName': 'Triflupromazine Hydrochloride', 'tradeNames_string': 'Vesprin', 'drugSynonyms_string': 'MC-4703, NSC-14959, NSC-17473, Triflupromazine hcl, Triflupromazine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_36', 'drugName': 'Promazine Hydrochloride', 'tradeNames_string': 'Prazine, Promazine Granules, Promazine hydrochloride, Protactyl, Sparine, Tranquazine, Verophene', 'drugSynonyms_string': 'NSC-17468, Promazine chloride, Promazine hcl, Promazine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1956, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2784', 'drugName': 'Chlorpromazine Hydrochloride', 'tradeNames_string': 'Chloractil, Chlorazine, Chlorpromazine hydrochloride, Chlorpromazine hydrochloride intensol, Largactil, Largactil fte, Promapar, Rimazine, Sonazine, Thorazine', 'drugSynonyms_string': 'Chlorpromazine HCl, Chlorpromazine hcl, Chlorpromazine hydrochloride, Chlorpromazini hydrochloridum, Klorproman, Marazine, NSC-17479, Nci-c05210, Norcozine', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_37', 'drugName': 'Promazine Hydrochloride', 'tradeNames_string': 'Prazine, Promazine Granules, Promazine hydrochloride, Protactyl, Sparine, Tranquazine, Verophene', 'drugSynonyms_string': 'NSC-17468, Promazine chloride, Promazine hcl, Promazine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1956, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1032 | Q17 | What gene does the drug Articaine target? | The drug Articaine targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%articaine%" OR LOWER(tradeNames_string) LIKE "%articaine%" OR LOWER(drugSynonyms_string) LIKE "%articaine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3040', 'drugName': 'Articaine', 'tradeNames_string': '', 'drugSynonyms_string': '40 045, 40-045, Articaine, Carticaine, HOE 045, HOE-045, Septocaine', 'linkedDiseasesDrug_string': 'Kidney Failure (EFO_1002048), Pain (EFO_0003843), Periodontitis (EFO_0000649), Pulpitis (EFO_1001139)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_1986', 'drugName': 'Articaine Hydrochloride', 'tradeNames_string': 'Septanest, Septocaine, Ultracaine', 'drugSynonyms_string': '40 045, Articaine hcl, Articaine hydrochloride, Carticaine hydrochloride, HOE 045, HOE-045, HOE-40045, Ubistesine, Ultracain', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.30 | Q17 | What gene does the drug Prochlorperazine Edisylate target? | The drug Prochlorperazine Edisylate targets the gene DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%prochlorperazine edisylate%" OR LOWER(tradeNames_string) LIKE "%prochlorperazine edisylate%" OR LOWER(drugSynonyms_string) LIKE "%prochlorperazine edisylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3536', 'drugName': 'Prochlorperazine Edisylate', 'tradeNames_string': 'Compazine, Prochlorperazine edisylate', 'drugSynonyms_string': 'NSC-757299, Prochlorperazine edisilate, Prochlorperazine edisylate, Prochlorperazine edisylate salt, Prochlorperazine ethanedisulfonate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.293 | Q17 | What gene does the drug Hydroxyzine Pamoate target? | The drug Hydroxyzine Pamoate targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hydroxyzine pamoate%" OR LOWER(tradeNames_string) LIKE "%hydroxyzine pamoate%" OR LOWER(drugSynonyms_string) LIKE "%hydroxyzine pamoate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1501', 'drugName': 'Hydroxyzine Pamoate', 'tradeNames_string': '"hy-pam ""25""", Hy-Pam "25", Hy-pam, Hydroxyzine pamoate, Vistaril', 'drugSynonyms_string': 'Hydroxyzine embonate, Hydroxyzine pamoate, NSC-757063', 'linkedDiseasesDrug_string': 'Anxiety Disorder (EFO_0006788), Skin Disease (EFO_0000701), Neurotic Disorder (EFO_0004257), Urticaria (EFO_0005531), Pruritus (HP_0000989)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1886 | Q17 | What gene does the drug Am-211 target? | The drug Am-211 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PTGDR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%am-211%" OR LOWER(tradeNames_string) LIKE "%am-211%" OR LOWER(drugSynonyms_string) LIKE "%am-211%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1306', 'drugName': 'Am-211', 'tradeNames_string': '', 'drugSynonyms_string': 'AM211, Am-211', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'PTGDR2 (ENSG00000183134)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1823 | Q17 | What gene does the drug Bumetanide target? | The drug Bumetanide targets the gene SLC12A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bumetanide%" OR LOWER(tradeNames_string) LIKE "%bumetanide%" OR LOWER(drugSynonyms_string) LIKE "%bumetanide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2656', 'drugName': 'Bumetanide', 'tradeNames_string': 'Betinex, Bumetanide, Bumex, Burinex, Lixil', 'drugSynonyms_string': 'Bumetanide, RO 10-6338, RO-10-6338, RO-106338, S-95008., S95008.', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Nephrotic Syndrome (EFO_0004255), Hepatocellular Carcinoma (EFO_0000182), Congestive Heart Failure (EFO_0000373), Chronic Kidney Disease (EFO_0003884), Heart Failure (EFO_0003144), Cardiovascular Disease (EFO_0000319), Kidney Disease (EFO_0003086), Seizure (HP_0001250), Hypokalemic Periodic Paralysis (MONDO_0008223), Type 2 Diabetes Mellitus (MONDO_0005148), Autism Spectrum Disorder (EFO_0003756)', 'yearOfFirstApproval': 1983, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC12A1 (ENSG00000074803)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.620 | Q17 | What gene does the drug Candesartan Cilexetil target? | The drug Candesartan Cilexetil targets the gene AGTR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%candesartan cilexetil%" OR LOWER(tradeNames_string) LIKE "%candesartan cilexetil%" OR LOWER(drugSynonyms_string) LIKE "%candesartan cilexetil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2579', 'drugName': 'Candesartan Cilexetil', 'tradeNames_string': 'Amias, Atacand, Candesartan cilexetil, Ratacand', 'drugSynonyms_string': 'Candesartan, Candesartan 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester, Candesartan cilexetil, NSC-758697, TCV-116', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Coronary Artery Disease (EFO_0001645), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Essential Hypertension (MONDO_0001134), Renal Artery Obstruction (EFO_1001150), Congestive Heart Failure (EFO_0000373), Breast Cancer (MONDO_0007254), Angina Pectoris (EFO_0003913), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Renovascular Hypertension (EFO_1001153), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Hypercholesterolemia (HP_0003124), Proteinuria (HP_0000093), Heart Failure (EFO_0003144), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AGTR1 (ENSG00000144891)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3868', 'drugName': 'Candesartan', 'tradeNames_string': '', 'drugSynonyms_string': 'CV-11974, Candesartan, Candesartan cilexetil related compound g, NSC-759858', 'linkedDiseasesDrug_string': "Alcoholic Liver Disease (EFO_0008573), Substance Abuse (MONDO_0002491), Peripheral Neuropathy (EFO_0003100), Migraine Without Aura (MONDO_0100431), Migraine Disorder (MONDO_0005277), Covid-19 (MONDO_0100096), Essential Hypertension (MONDO_0001134), Hepatitis C Virus Infection (EFO_0003047), Atrial Fibrillation (EFO_0000275), Congestive Heart Failure (EFO_0000373), Migraine With Aura (MONDO_0005475), Left Ventricular Hypertrophy (EFO_0003896), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Cocaine Dependence (EFO_0002610), Dilated Cardiomyopathy (EFO_0000407), Methamphetamine Dependence (EFO_0004701), Aortic Stenosis (EFO_0000266), Bipolar Disorder (MONDO_0004985), Heart Disease (EFO_0003777), Cognitive Impairment (HP_0100543), Heart Failure (EFO_0003144), Hypertrophic Cardiomyopathy (EFO_0000538), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Barrett'S Esophagus (EFO_0000280)", 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'AGTR1 (ENSG00000144891)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1667 | Q17 | What gene does the drug Etirinotecan Pegol target? | The drug Etirinotecan Pegol is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TOP1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%etirinotecan pegol%" OR LOWER(tradeNames_string) LIKE "%etirinotecan pegol%" OR LOWER(drugSynonyms_string) LIKE "%etirinotecan pegol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4848', 'drugName': 'Etirinotecan Pegol', 'tradeNames_string': '', 'drugSynonyms_string': 'Etirinotecan pegol, NKTR-102', 'linkedDiseasesDrug_string': 'Anaplastic Astrocytoma (EFO_0002499), Cancer (MONDO_0004992), Anaplastic Oligodendroglioma (EFO_0002501), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519), Colorectal Carcinoma (EFO_1001951), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TOP1 (ENSG00000198900)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.850 | Q17 | What gene does the drug Trilostane target? | The drug Trilostane targets the gene HSD3B2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trilostane%" OR LOWER(tradeNames_string) LIKE "%trilostane%" OR LOWER(drugSynonyms_string) LIKE "%trilostane%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2278', 'drugName': 'Trilostane', 'tradeNames_string': 'Modrastane, Modrenal', 'drugSynonyms_string': 'Desopan, NSC-758904, Trilostane, WIN 24,540, WIN-24540', 'linkedDiseasesDrug_string': 'Prostate Adenocarcinoma (EFO_0000673), Adrenal Gland Disease (EFO_0005539)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HSD3B2 (ENSG00000203859)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.215 | Q17 | What gene does the drug Ravulizumab target? | The drug Ravulizumab targets the gene C5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ravulizumab%" OR LOWER(tradeNames_string) LIKE "%ravulizumab%" OR LOWER(drugSynonyms_string) LIKE "%ravulizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_629', 'drugName': 'Ravulizumab', 'tradeNames_string': 'Ultomiris', 'drugSynonyms_string': 'ALXN-1210, ALXN1210, Ravulizumab, Ravulizumab cwvz, Ravulizumab-cwvz', 'linkedDiseasesDrug_string': 'Acute Lung Injury (EFO_0004610), Amyotrophic Lateral Sclerosis (MONDO_0004976), Viral Pneumonia (EFO_0007541), Hemolytic-Uremic Syndrome (MONDO_0001549), Atypical Hemolytic-Uremic Syndrome (MONDO_0016244), Neuromyelitis Optica (EFO_0004256), Acute Respiratory Distress Syndrome (EFO_1000637), Thrombotic Microangiopathy (MONDO_0019737), Myasthenia Gravis (EFO_0004991), Dermatomyositis (EFO_0000398), Immune System Disease (EFO_0000540)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'C5 (ENSG00000106804)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.524 | Q17 | What gene does the drug Ribociclib Succinate target? | The drug Ribociclib Succinate targets 2 genes: CDK4 and CDK6. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ribociclib succinate%" OR LOWER(tradeNames_string) LIKE "%ribociclib succinate%" OR LOWER(drugSynonyms_string) LIKE "%ribociclib succinate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2092', 'drugName': 'Ribociclib Succinate', 'tradeNames_string': 'Kisqali', 'drugSynonyms_string': 'Birociclib, LEE-011-BBA, LEE011-BBA, Ribociclib succinate', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Breast Cancer (MONDO_0007254), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK4 (ENSG00000135446), CDK6 (ENSG00000105810)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2093', 'drugName': 'Ribociclib Succinate', 'tradeNames_string': 'Kisqali', 'drugSynonyms_string': 'Birociclib, LEE-011-BBA, LEE011-BBA, Ribociclib succinate', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Breast Cancer (MONDO_0007254), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK4 (ENSG00000135446), CDK6 (ENSG00000105810)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.477 | Q17 | What gene does the drug Melatonin target? | The drug Melatonin targets 2 genes: MTNR1B and MTNR1A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%melatonin%" OR LOWER(tradeNames_string) LIKE "%melatonin%" OR LOWER(drugSynonyms_string) LIKE "%melatonin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5737', 'drugName': 'Melatonin', 'tradeNames_string': "Circadin, General nutrit, Health aid, Heidadouppi, Icenia, Life ext, Melapure, Natrol, Nature's blend, Natures bounty, Quality health, S.gard, Travelag, Vespro, Vytalonin", 'drugSynonyms_string': '5-methoxy n-acetyl-tryptamine, BCI-049, J5.258B, Melatol, Melatonin, Melatonine, Melovine, N-(2-(5-Methoxy-1H-Indol-3-Yl)Ethyl)Acetamide, N-Acetyl-5-Methoxytryptamine, NSC-113928, NSC-302012, NSC-56423, Regulin, Tartrol', 'linkedDiseasesDrug_string': "Autism (EFO_0003758), Diabetes Mellitus (EFO_0000400), Cancer (MONDO_0004992), Multiple Sclerosis (MONDO_0005301), Hemorrhage (MP_0001914), Dengue Disease (EFO_0005547), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Migraine Disorder (MONDO_0005277), Essential Hypertension (MONDO_0001134), Irritable Bowel Syndrome (EFO_0000555), Injury (EFO_0000546), Ulcerative Colitis (EFO_0000729), Hot Flashes (HP_0031217), Metabolic Disease (EFO_0000589), Atrial Fibrillation (EFO_0000275), Osteopenia (HP_0000938), Substance Withdrawal Syndrome (EFO_0005800), Tooth Disease (EFO_1001216), Breast Cancer (MONDO_0007254), Atopic Eczema (EFO_0000274), Hypertension (EFO_0000537), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Attention Deficit Hyperactivity Disorder (EFO_0003888), Fibromyalgia (EFO_0005687), Acute Myocardial Infarction (EFO_0008583), Necrotizing Enterocolitis (EFO_0003928), Periodontitis (EFO_0000649), Epilepsy (EFO_0000474), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Oral Squamous Cell Carcinoma (EFO_0000199), Brain Ischemia (MONDO_0005299), Autism Spectrum Disorder (EFO_0003756), Sunburn (EFO_0003958), Sleep Disorder (EFO_0008568), Sepsis (HP_0100806), Enuresis (MONDO_0024290), Aortic Aneurysm (EFO_0001666), Delirium (EFO_0009267), Neonatal Sepsis (HP_0040187), Periodontal Disorder (MONDO_0002635), Barrett'S Esophagus (EFO_0000280), Obstructive Sleep Apnea (EFO_0003918), Depressive Disorder (MONDO_0002050), Alcohol-Related Disorders (MONDO_0021698), Postpartum Hemorrhage (EFO_0009579), Gastroesophageal Reflux Disease (EFO_0003948), Insomnia (EFO_0004698), Head And Neck Malignant Neoplasia (EFO_0006859), Asphyxia Neonatorum (EFO_1000824), Ischemia Reperfusion Injury (EFO_0002687), Neoplasm (EFO_0000616), Cognitive Impairment (HP_0100543), Non-Small Cell Lung Carcinoma (EFO_0003060), Burn (EFO_0009516), Metabolic Syndrome (EFO_0000195), Melanoma (EFO_0000756), Acute Kidney Injury (HP_0001919), Skin Disease (EFO_0000701), Major Depressive Disorder (MONDO_0002009), Fatigue (HP_0012378), Prediabetes Syndrome (EFO_1001121), Anxiety (EFO_0005230), Oral Mucositis (EFO_1001904), Schizophrenia (MONDO_0005090)", 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MTNR1A (ENSG00000168412), MTNR1B (ENSG00000134640)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1327 | Q17 | What gene does the drug Aliskiren Fumarate target? | The drug Aliskiren Fumarate targets the gene REN. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aliskiren fumarate%" OR LOWER(tradeNames_string) LIKE "%aliskiren fumarate%" OR LOWER(drugSynonyms_string) LIKE "%aliskiren fumarate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4221', 'drugName': 'Aliskiren Fumarate', 'tradeNames_string': 'Tekturna', 'drugSynonyms_string': 'Aliskiren fumarate, Aliskiren hemifumarate, NSC-759185, SPP-100B, SPP100', 'linkedDiseasesDrug_string': 'Stroke (EFO_0000712), Hypertension (EFO_0000537)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'REN (ENSG00000143839)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1433 | Q17 | What gene does the drug Esomeprazole Magnesium target? | The drug Esomeprazole Magnesium targets 2 genes: ATP4B and ATP4A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%esomeprazole magnesium%" OR LOWER(tradeNames_string) LIKE "%esomeprazole magnesium%" OR LOWER(drugSynonyms_string) LIKE "%esomeprazole magnesium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4440', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_string': 'Esomeprazole magnesium, Nexium, Nexium 24hr', 'drugSynonyms_string': 'Esomeprazole (as magnesium), Esomeprazole magnesium, Esomeprazole magnesium hydrate, Esomeprazole magnesium trihydrate, H199/18 MAGNESIUM TRIHYDRATE', 'linkedDiseasesDrug_string': 'Esophagitis (HP_0100633), Osteoarthritis (MONDO_0005178), Ankylosing Spondylitis (EFO_0003898), Type 2 Diabetes Mellitus (MONDO_0005148), Gastric Ulcer (EFO_0009454), Duodenal Ulcer (EFO_0004607), Rheumatoid Arthritis (EFO_0000685), Chronic Pancreatitis (EFO_0000342), Zollinger-Ellison Syndrome (EFO_0007549), Helicobacter Pylori Infectious Disease (EFO_1000961), Gastroesophageal Reflux Disease (EFO_0003948), Peptic Ulcer Disease (MONDO_0004247)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.123 | Q17 | What gene does the drug Sargramostim target? | The drug Sargramostim targets 2 genes: CSF2RB and CSF2RA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sargramostim%" OR LOWER(tradeNames_string) LIKE "%sargramostim%" OR LOWER(drugSynonyms_string) LIKE "%sargramostim%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5636', 'drugName': 'Sargramostim', 'tradeNames_string': 'Leukine', 'drugSynonyms_string': 'B1 61.012, B1-61012, Granulocyte-macrophage colony-stimulating factor sargramostim, RHU GM-CSF, RHU-GM-CSF, Sargramostim, Sargramostim rdna', 'linkedDiseasesDrug_string': "Ovarian Carcinoma (EFO_0001075), Multiple Myeloma (EFO_0001378), Infection (EFO_0000544), Cytomegalovirus Retinitis (EFO_1001302), Malignant Colon Neoplasm (MONDO_0021063), Malignant Glioma (MONDO_0100342), Inflammatory Breast Carcinoma (EFO_1000984), Myelodysplastic/Myeloproliferative Disease (MONDO_0020077), Hiv-1 Infection (EFO_0000180), Brain Neoplasm (EFO_0003833), Carcinoma (EFO_0000313), Breast Ductal Carcinoma In Situ (EFO_0000432), Liver Cancer (MONDO_0002691), Follicular Lymphoma (MONDO_0018906), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Down Syndrome (EFO_0001064), Kidney Disease (EFO_0003086), Cutaneous Leishmaniasis (EFO_0005046), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Acute Myeloid Leukemia By Fab Classification (MONDO_0015667), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Prostate Carcinoma (EFO_0001663), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Mantle Cell Lymphoma (EFO_1001469), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Metastasis (EFO_0009708), Triple-Negative Breast Cancer (EFO_0005537), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Pulmonary Alveolar Proteinosis (MONDO_0001437), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Peripheral Arterial Disease (EFO_0004265), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Chronic Hepatitis B Virus Infection (EFO_0004239), Lymphoma (EFO_0000574), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Pouchitis (EFO_0003921), Periodontitis (EFO_0000649), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Congenital Pulmonary Alveolar Proteinosis (Orphanet_264675), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Abnormality Of Blood And Blood-Forming Tissues (HP_0001871), Gallbladder Cancer (MONDO_0005411), Colorectal Cancer (MONDO_0005575), Fever (HP_0001945), Ganglioneuroblastoma (EFO_0000502), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Cutaneous Melanoma (EFO_0000389), Biliary Tract Neoplasm (EFO_0003891), Chronic Myeloproliferative Disorder (EFO_0002428), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Urinary Bladder Cancer (MONDO_0001187), Sarcoma (EFO_0000691), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Metastatic Melanoma (EFO_0002617), Burkitts Lymphoma (EFO_0000309), Myasthenia Gravis (EFO_0004991), Plasma Cell Leukemia (EFO_0006475), Endometrial Cancer (MONDO_0011962), Chronic Myelogenous Leukemia (EFO_0000339), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Neutropenia (MONDO_0001475), Colorectal Neoplasm (EFO_0004142), Parkinson Disease (MONDO_0005180), Male Breast Carcinoma (EFO_0006861), Oral Squamous Cell Carcinoma (EFO_0000199), Refractory Anemia With Excess Blasts (EFO_0003811), Sepsis (HP_0100806), Renal Cell Carcinoma (EFO_0000681), Rheumatoid Arthritis (EFO_0000685), Endometrioid Carcinoma (EFO_0000466), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Mesenchymoma (EFO_1001042), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Severe Acute Respiratory Syndrome (EFO_0000694), Esophageal Cancer (MONDO_0007576)", 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CSF2RA (ENSG00000198223), CSF2RB (ENSG00000100368)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1351 | Q17 | What gene does the drug Barnidipine target? | The drug Barnidipine is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 4 genes: CACNA1C, CACNA1D, CACNA1S and CACNA1F | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%barnidipine%" OR LOWER(tradeNames_string) LIKE "%barnidipine%" OR LOWER(drugSynonyms_string) LIKE "%barnidipine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1479', 'drugName': 'Barnidipine', 'tradeNames_string': '', 'drugSynonyms_string': 'Barnidipine, Barnidipine hydrochloride, Mepirodipine, Vasexten', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': -1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1942 | Q17 | What gene does the drug Uproleselan target? | The drug Uproleselan is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene SELE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%uproleselan%" OR LOWER(tradeNames_string) LIKE "%uproleselan%" OR LOWER(drugSynonyms_string) LIKE "%uproleselan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2418', 'drugName': 'Uproleselan', 'tradeNames_string': '', 'drugSynonyms_string': 'GMI-1271, GMI-1271 FREE ACID, Uproleselan', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222), Deep Vein Thrombosis (EFO_0003907), Covid-19 (MONDO_0100096), Multiple Myeloma (EFO_0001378)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'SELE (ENSG00000007908)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1371 | Q17 | What gene does the drug Enoximone target? | The drug Enoximone targets 2 genes: PDE3A and PDE3B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%enoximone%" OR LOWER(tradeNames_string) LIKE "%enoximone%" OR LOWER(drugSynonyms_string) LIKE "%enoximone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3544', 'drugName': 'Enoximone', 'tradeNames_string': 'Perfan', 'drugSynonyms_string': 'Enoximone, MDL 17,043, MDL-17043', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Coronary Artery Disease (EFO_0001645), Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE3A (ENSG00000172572), PDE3B (ENSG00000152270)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1171 | Q17 | What gene does the drug Fluphenazine Hydrochloride target? | The drug Fluphenazine Hydrochloride targets the gene DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fluphenazine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%fluphenazine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%fluphenazine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5319', 'drugName': 'Fluphenazine Hydrochloride', 'tradeNames_string': 'Fluphenazine hydrochloride, Moditen, Permitil, Prolixin', 'drugSynonyms_string': 'Fluphenazine dihydrochloride, Fluphenazine hydrochloride, NSC-179197, SQUIBB 4918', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.138 | Q17 | What gene does the drug Cipralisant Maleate target? | The drug Cipralisant Maleate is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene HRH3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cipralisant maleate%" OR LOWER(tradeNames_string) LIKE "%cipralisant maleate%" OR LOWER(drugSynonyms_string) LIKE "%cipralisant maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5091', 'drugName': 'Cipralisant Maleate', 'tradeNames_string': 'Perceptin', 'drugSynonyms_string': 'Cipralisant maleate, GT-2331, Gt2331', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'HRH3 (ENSG00000101180)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1134 | Q17 | What gene does the drug Cobolimab target? | The drug Cobolimab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene HAVCR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cobolimab%" OR LOWER(tradeNames_string) LIKE "%cobolimab%" OR LOWER(drugSynonyms_string) LIKE "%cobolimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5425', 'drugName': 'Cobolimab', 'tradeNames_string': '', 'drugSynonyms_string': 'Cobolimab, TSR-022, Tsr 022, Tsr-022, WBP-296A', 'linkedDiseasesDrug_string': 'Melanoma (EFO_0000756), Non-Small Cell Lung Carcinoma (EFO_0003060), Liver Cancer (MONDO_0002691), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'HAVCR2 (ENSG00000135077)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1874 | Q17 | What gene does the drug Norgestimate target? | The drug Norgestimate targets the gene PGR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%norgestimate%" OR LOWER(tradeNames_string) LIKE "%norgestimate%" OR LOWER(drugSynonyms_string) LIKE "%norgestimate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4354', 'drugName': 'Norgestimate', 'tradeNames_string': '', 'drugSynonyms_string': 'Dexnorgestrel acetime, NSC-759159, Norgestimate, ORF 10131, ORF-10131, RWJ 10131, RWJ-10131', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Hiv Infection (EFO_0000764), Migraine Disorder (MONDO_0005277), Metrorrhagia (HP_0100608), Neural Tube Defect (MONDO_0018075), Cystic Fibrosis (MONDO_0009061), Acne (EFO_0003894), Hepatitis C Virus Infection (EFO_0003047)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2301', 'drugName': 'Norelgestromin', 'tradeNames_string': 'Evra, Ortho evra', 'drugSynonyms_string': 'Deacetylnorgestimate, Norelgestromin, RWJ-10553', 'linkedDiseasesDrug_string': 'Pregnancy (EFO_0002950), Metrorrhagia (HP_0100608), Hiv Infection (EFO_0000764)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1241 | Q17 | What gene does the drug Ipratropium target? | The drug Ipratropium targets the gene CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ipratropium%" OR LOWER(tradeNames_string) LIKE "%ipratropium%" OR LOWER(drugSynonyms_string) LIKE "%ipratropium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4927', 'drugName': 'Ipratropium Bromide', 'tradeNames_string': 'Atrovent, Atrovent aerocaps, Atrovent fte, Atrovent hfa, Atrovent udvs, Ipratrop, Ipratrop steripoule, Ipratropium bromide, Respontin, Rinatec, Tropiovent', 'drugSynonyms_string': 'Ipratropium bromide, Ipratropium bromide anhydrous, Ipratropium bromide hydrate, Ipratropium bromide monohydrate, NSC-759613, SCH 1000-BR-MONOHYDRATE, SCH-1000-BR-', 'linkedDiseasesDrug_string': 'Nasal Congestion (HP_0001742), Chronic Bronchitis (EFO_0006505), Bronchospasm (HP_0025428), Common Cold (EFO_0007214), Asthma (MONDO_0004979), Seasonal Allergic Rhinitis (EFO_0003956), Atopic Eczema (EFO_0000274), Drooling (HP_0002307), Chronic Obstructive Pulmonary Disease (EFO_0000341), Parkinson Disease (MONDO_0005180), Pulmonary Arterial Hypertension (EFO_0001361), Airway Obstruction (HP_0006536), Emphysema (EFO_0000464), Familial Dysautonomia (Orphanet_1764)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3538', 'drugName': 'Ipratropium', 'tradeNames_string': '', 'drugSynonyms_string': 'Ipratropium, Ipratropium cation, Ipratropium ion', 'linkedDiseasesDrug_string': 'Status Asthmaticus (EFO_0008590), Chronic Bronchitis (EFO_0006505), Bronchospasm (HP_0025428), Nasal Congestion (HP_0001742), Common Cold (EFO_0007214), Asthma (MONDO_0004979), Seasonal Allergic Rhinitis (EFO_0003956), Atopic Eczema (EFO_0000274), Drooling (HP_0002307), Chronic Obstructive Pulmonary Disease (EFO_0000341), Parkinson Disease (MONDO_0005180), Pulmonary Arterial Hypertension (EFO_0001361), Airway Obstruction (HP_0006536), Emphysema (EFO_0000464), Familial Dysautonomia (Orphanet_1764)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1338 | Q17 | What gene does the drug Metaproterenol target? | The drug Metaproterenol targets the gene ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%metaproterenol%" OR LOWER(tradeNames_string) LIKE "%metaproterenol%" OR LOWER(drugSynonyms_string) LIKE "%metaproterenol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1717', 'drugName': 'Metaproterenol', 'tradeNames_string': '', 'drugSynonyms_string': 'Metaproterenol, Orciprenaline', 'linkedDiseasesDrug_string': 'Airway Obstruction (HP_0006536), Asthma (MONDO_0004979), Drug Dependence (EFO_0003890)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5266', 'drugName': 'Metaproterenol Sulfate', 'tradeNames_string': 'Alupent, Alupent obstetric, Metaproterenol sulfate, Prometa', 'drugSynonyms_string': 'Metaproterenol sulfate, Metaproterenol sulphate, Orciprenaline sulfate, Orciprenaline sulphate, TH-152', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Drug Dependence (EFO_0003890)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.